var title_f36_9_37008="Slit lamp beam height";
var content_f36_9_37008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Slit lamp beam height",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adjust slit lamp beam for a tall, narrow vertical beam of white light.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37008=[""].join("\n");
var outline_f36_9_37008=null;
var title_f36_9_37009="Defining the bladder";
var content_f36_9_37009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Defining the bladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37009=[""].join("\n");
var outline_f36_9_37009=null;
var title_f36_9_37010="MR from perforated leaflet transesophageal color Doppler echo";
var content_f36_9_37010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/58795/teecmrpl_conv.mp4?title=MR+from+perforated+leaflet+transesophageal+color+Doppler+echo\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral regugitation due to anterior leaflet perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 254px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows mitral regurgitation with a narrow \"jet\" through a perforated anterior mitral valve (MV) leaflet. The left atrium is enlarged as a result of the regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37010=[""].join("\n");
var outline_f36_9_37010=null;
var title_f36_9_37011="Bladder removal PI";
var content_f36_9_37011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    How urine leaves the body after the bladder is removed",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After removing a person's bladder, the surgeon must create a new way for urine to leave the body. There are 3 ways to do this:",
"    <br>",
"     (A) The surgeon can connect the ureters to a tube that drains through a hole on the surface of the skin. This is called a stoma. People who have a stoma must attach a bag around the outside of the stoma to collect urine.",
"     <br>",
"      (B) The surgeon can connect the ureters to a pouch that collects urine and then connect it to a stoma. People who have a pouch must drain the pouch every few hours by inserting a tube into the stoma.",
"      <br>",
"       (C) The surgeon can connect the ureters to a pouch that collects urine and then connect it to the urethra. That way, urine can leave the body the same way it did before. (The pouch used in this procedure is basically a new bladder. Surgeons call it a \"neobladder\".)",
"       <br>",
"        These options are not possible in all people. Ask your doctor which options could work for you. Then work with him or her to choose the best approach for you.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37011=[""].join("\n");
var outline_f36_9_37011=null;
var title_f36_9_37012="Alfuzosin: Patient drug information";
var content_f36_9_37012=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Alfuzosin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/55/26485?source=see_link\">",
"     see \"Alfuzosin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Uroxatral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Alfuzosin&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Alfuzosin;",
"     </li>",
"     <li>",
"      Teva-Alfuzosin PR;",
"     </li>",
"     <li>",
"      Xatral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In men, it is used to treat the signs of an enlarged prostate.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat kidney stones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to alfuzosin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having cataract surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a rectal exam (to check prostate gland) and blood work (PSA test). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11477 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37012=[""].join("\n");
var outline_f36_9_37012=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131552\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131553\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017438\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017440\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017439\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017444\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017445\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017447\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017442\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017443\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017448\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017449\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/55/26485?source=related_link\">",
"      Alfuzosin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_9_37013="Medullary thyroid carcinoma";
var content_f36_9_37013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medullary carcinoma of the thyroid: Findings on surgical histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen showing typical histologic appearance of medullary carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37013=[""].join("\n");
var outline_f36_9_37013=null;
var title_f36_9_37014="Removal of unwanted hair";
var content_f36_9_37014=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Removal of unwanted hair",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37014/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37014/contributors\">",
"     Donald W Shenenberger, MD, FAAD, FAAFP, CDR, MC, USN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37014/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37014/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37014/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37014/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37014/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/9/37014/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of post-pubertal persons in the world regularly practice some form of hair removal. Be it by shaving, plucking, or by other methods, most of us have hair on some part of our bodies that we try to remove.",
"   </p>",
"   <p>",
"    This topic reviews options for removal of unwanted hair. There are only limited data from clinical trials, so much of the information presented here is based on expert opinion. The evaluation and management of hirsutism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/28/24007?source=see_link\">",
"     \"Pathogenesis and causes of hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link\">",
"     \"Evaluation of premenopausal women with hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HAIR GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are born with all the hair follicles we will ever have [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/1\">",
"     1",
"    </a>",
"    ]. At puberty, as a result of androgenic effects, some of these follicles enlarge and produce their characteristic growth patterns (beard growth, pubic hair). In some people, hair growth has a strong genetic influence leading to some of the more predictable ethnic patterns of hair distribution and thickness. The cells of the matrix at the base of the hair shaft differentiate under the influence of the dermal papilla and then proliferate to form the growing hair. Melanocytes within the matrix give the hair its color. The primary growth phase of the hair is called anagen, and it makes up the majority of the time a hair spends in the growth cycle. The other two phases are called catagen and telogen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13846?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonscarring hair loss\", section on 'Hair growth cycle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During catagen, the hair follicle involutes, bringing an end to the active growth phase (anagen). The next phase, telogen, is the quiescent or resting phase that typically lasts for several months. At this stage, hair may be shed by brushing or during washing. Most hairs spend the majority of time in anagen (80 to 90 percent of the growth phase); however, this depends upon where the hairs are located. Scalp hairs typically spend the most time in anagen and can remain in anagen for several years before transitioning to telogen. Eyebrows and lashes have a much shorter anagen phase, and thus a relatively shorter length. It is during anagen that a hair is most susceptible to some of the newer methods of removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REMOVAL OPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Temporary methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following methods typically result in only temporary removal of hair; however, in some circumstances the dermal papilla may be damaged by the removal, leading to permanent removal of hair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Plucking/epilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relatively safe and inexpensive method of hair removal is epilation, better known as plucking. The term \"epilation\" means to extract hair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/4\">",
"     4",
"    </a>",
"    ]. Plucked hairs can remain absent for six to eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ]. However, plucking can be very uncomfortable and time consuming. Further, epilation can cause irritation (folliculitis) due to the traumatic nature of the procedure.",
"   </p>",
"   <p>",
"    Plucking hairs during anagen probably maximizes the effect and increases the likelihood of destroying the dermal papilla, which would lead to permanent hair removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2\">",
"     2",
"    </a>",
"    ]. In general, though, hair typically regrows after being plucked. In a study that compared axillary hair plucking with electrolysis, plucking did not reduce hair counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plucking can be performed with tweezers, by use of thin threads (threading), or any one of a number of commercially available devices and is best suited for relatively small areas such as the face.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Waxing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Waxing, which is technically a form of epilation, involves applying a layer of wax to the area where hair removal is desired. When the wax is pulled off, the trapped hairs are pulled out. Although operator dependent, waxing may be less painful than plucking individual hairs.",
"   </p>",
"   <p>",
"    Waxing can be performed with either a molten wax or a room temperature liquid wax (called cold wax). The hot wax treatment causes follicular dilatation allowing entire hairs to be removed down to the bulb. The \"cold wax\" treatment sometimes uses an added resin to entrap hairs and allow them to be pulled out, also at the bulb.",
"   </p>",
"   <p>",
"    Waxing can be used on a broad range of body areas such as eyebrows, back, bikini area, and legs. As long as the hairs are removed with the bulb intact, one can expect similar results to plucking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Depilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depilation is the use of a chemical (a depilatory agent) to essentially dissolve the hair. The active ingredients in most products are thioglycolates, which disrupt disulfide bonds in the hair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2\">",
"     2",
"    </a>",
"    ]. The end result is dissolution of the hair into a gelatinous form, which can be wiped or scraped away.",
"   </p>",
"   <p>",
"    Depilatories work well, but the results do not typically last much longer than two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, since most depilatories are sulfur-containing compounds, the odor produced can be unpleasant.",
"   </p>",
"   <p>",
"    Depilatories are used most often on bikini areas and legs but can be used on various areas of the body. Depilatories may be particularly useful in men with severe ingrowing of facial hair (pseudofolliculitis barbae); however, when used for this purpose they may cause severe irritation leading to postinflammatory hyperpigmentation in some individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36343?source=see_link&amp;anchor=H1015969#H1015969\">",
"     \"Pseudofolliculitis barbae\", section on 'Depilatories'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Irritant dermatitis can occur with the use of depilatories. Different strengths and compounds can be tried if irritation occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Shaving",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shaving is a popular method of hair removal. Methods of variable expense are available including old-fashioned straight razors, multiple blade safety razors, and electric shavers.",
"   </p>",
"   <p>",
"    Shaving only removes hair down to just below the surface of the skin. When used for facial hair, most people must repeat the process daily with some needing retreatment in less than 12 hours. The process is purely mechanical and provides only shortening of the hair involved. Most body areas are amenable to shaving.",
"   </p>",
"   <p>",
"    Shaving does not cause hair to grow back thicker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. Rather, the sharp, beveled edge created from the shearing off of the hair creates the rough texture. Thickening of hair is produced by exposure to androgens either as a normal result of sexual maturity or in pathologic disease states.",
"   </p>",
"   <p>",
"    Shaving can produce skin irritation either from the cutting process of the blade, or from the shaving creams, gels, and other facial preparations intended to smooth the process. Pseudofolliculitis barbae (razor bumps, shave bumps) is a common complication, particularly in black men. Shaving also may nick or abrade the epidermis, increasing the risk for superficial infection (eg, folliculitis) by bacteria such as staphylococcus aureus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36343?source=see_link\">",
"     \"Pseudofolliculitis barbae\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=see_link\">",
"     \"Folliculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, shaving can lead to the spread of viral warts or molluscum contagiosum. It is advisable to avoid shaving the involved areas entirely, especially during treatment of warts or molluscum. Patients who have these lesions and still choose to shave should be advised to not use the same razor on other areas of the body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bleaching",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not a method of hair removal, bleaching is a relatively common method for masking the presence of undesired hair, particularly facial hair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/9\">",
"     9",
"    </a>",
"    ]. A variety of products are available, all of which contain",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    and sulfates. These components lighten and soften the hair, making it less conspicuous.",
"   </p>",
"   <p>",
"    Patients can develop a reaction to the active ingredients, as with all chemical methods of hair control. Side effects include irritation, pruritus, and possible skin discoloration. In addition, patients with sensitivity to sulfa may want to avoid these products. Testing the product on a small area of skin prior to use may help the patient avoid a more pronounced reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pharmacologic options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic treatment of hirsutism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35416?source=see_link\">",
"     \"Treatment of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     Eflornithine",
"    </a>",
"    13.9% cream (Vaniqa) can reduce hair growth by irreversible inhibition of ornithine decarboxylase, an enzyme important for normal hair growth; it is approved by the US Food and Drug Administration (FDA) for removal of facial hair in women. Unpublished data from the manufacturer on two randomized trials involving 594 women treated for 24 weeks found that more women had at least marked improvement with eflornithine than with placebo (32 versus 8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/10\">",
"     10",
"    </a>",
"    ]. Noticeable results take about six to eight weeks, and once the cream is discontinued hair returns to pretreatment levels after about eight weeks.",
"   </p>",
"   <p>",
"    Clinical trials have also found that combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    with laser hair removal results in a more rapid response than laser treatment alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     Eflornithine",
"    </a>",
"    can cause an acneiform reaction in 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/13\">",
"     13",
"    </a>",
"    ]. Systemic absorption is low when it is applied topically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laser and intense pulsed light",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photoepilation therapies (laser and intense pulsed noncoherent light sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/15\">",
"     15",
"    </a>",
"    ]) can be used to reduce hair via selective photothermolysis. Total removal of hair is uncommon, and realistic expectations for treatment include less hair, lighter hair, and thinner hair. In general, dark hair responds best.",
"   </p>",
"   <p>",
"    Coupling the absorption characteristics of a target (melanin in the case of hair, also known as the \"chromophore\") with a laser of a corresponding wavelength allows for the selective targeting of the specific chromophore within the matrix. Ideally, the wavelength of laser light should be selectively absorbed by melanin only within the hair bulb, thus destroying only the hair and theoretically resulting in permanent removal. However, competing structures within adjacent skin can cause laser energy to be absorbed by pigment in the epidermis in addition to melanin within the hair bulb, thus reducing the effectiveness of the treatment and increasing the potential for adverse effects.",
"   </p>",
"   <p>",
"    An early study of 183 patients of varying skin phototypes who were treated over the course of a year with up to six treatments with a 694 nm ruby laser found that six months after a single treatment, 67 percent of patients had a greater than 50 percent reduction in hair at the treatment site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/16\">",
"     16",
"    </a>",
"    ]. Multiple treatments increased the percentage of patients with 50 percent reduction to 90 percent. However, by one year there was a return of fine vellus hair in the majority of patients. All body sites were represented in this study. More modern lasers now allow better selective photothermolysis with less potential for complications.",
"   </p>",
"   <p>",
"    Several different wavelengths of laser or intense pulsed light (IPL) are available for photoepilation (",
"    <a class=\"graphic graphic_table graphicRef77792 \" href=\"mobipreview.htm?35/37/36443\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The ideal subjects for laser hair removal are light skinned people with dark hair in whom most of the laser energy is absorbed by melanin in the hair bulb rather than by the surrounding epidermis. The efficacy of most lasers and IPL is greatest for darker pigmented hair (black &gt; brown &gt; gray, red, or blonde &gt; white), while the risk of burns and skin tone interference increases with increasing skin pigmentation. However, continued advances in laser technology have given those with darker skin better options for laser hair removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. As an example, a study in 144 Asian subjects with Fitzpatrick skin types III to V found that treatment with a long-pulsed alexandrite laser (755 nm) could effectively remove hair without scarring or long-term pigment changes; hair reduction at nine months was greater after three treatments than with two or one (hair reduction of 55, 44, and 32 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One popular laser used for hair removal in individuals with dark skin is the 1064 nm long-pulsed neodymium:yttrium-aluminum-garnet (Nd-YAG) laser. It has demonstrated efficacy in all skin types and is particularly effective in those with darker skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/21\">",
"     21",
"    </a>",
"    ]. It is particularly helpful in patients with pseudofolliculitis barbae.",
"   </p>",
"   <p>",
"    Success rates of laser therapy are not completely explained by hair growth phase and melanin content [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/23\">",
"     23",
"    </a>",
"    ]; overall success is likely determined by a combination of hair location, skin and hair color, the stage of hair growth, laser type, and treatment plan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the hair matrix is most sensitive to laser treatment while it is in the anagen phase, multiple treatments are necessary. This is to ensure all hairs have been treated during this most sensitive phase of growth. Patients typically require four to six treatments spaced approximately four to six weeks apart in order to achieve satisfactory hair removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/22\">",
"     22",
"    </a>",
"    ]. Adjustments of laser settings are often needed for optimal results. Once the primary course is complete, patients may require maintenance treatments once every 6 to 12 months to remove the smaller vellus hairs that may grow back.",
"   </p>",
"   <p>",
"    IPL systems have been shown to be as effective as laser in hair removal. An intense pulsed light system makes use of a flash-lamp that produces intense light of a range of wavelengths depending on the intended target. IPL systems also can be used for the treatment of pigmented and vascular lesions.",
"   </p>",
"   <p>",
"    Laser or IPL therapy is probably best suited for people who desire treatment of large areas or areas with dense hair growth, but like electrolysis, can also be used for smaller areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/18\">",
"     18",
"    </a>",
"    ]. Laser or intense pulsed light can cause irritation and postinflammatory pigment changes. In addition, pain, erythema, blistering, and scarring are possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/18,19,21,24,25\">",
"     18,19,21,24,25",
"    </a>",
"    ]. Paradoxical hypertrichosis of the treated areas appears to be a rare complication of laser therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Photoepilation therapies are the most expensive methods of hair",
"    <span class=\"nowrap\">",
"     removal/reduction.",
"    </span>",
"    A systematic review found two trials that suggested that laser therapy was more effective than electrolysis; however, these trials were very small and had other methodologic problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Electrolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrolysis, if performed properly, is technically the only permanent method of hair removal. However, since technique can vary among electrologists, many patients can experience hair regrowth. This method is rarely performed by physicians, but may be offered in a \"spa-like\" setting as one of several methods for hair removal.",
"   </p>",
"   <p>",
"    Electrolysis is performed by inserting a very fine needle into the hair follicle and applying an electrical current. The basis of its therapeutic effect is the destruction of the rapidly dividing cells of the matrix and the follicle itself.",
"   </p>",
"   <p>",
"    First reported in 1875, electrolysis began with the use of direct current, also called galvanic electrolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/28\">",
"     28",
"    </a>",
"    ]. In the galvanic method, the destruction occurs as a result of the electrical effect on saline in tissues. Sodium hydroxide is produced at the tip of the needle causing the chemical destruction of the hair bulb and dermal papilla. Galvanic electrolysis is a slow process.",
"   </p>",
"   <p>",
"    The development of thermolytic electrolysis using high frequency alternating current (commonly 13.56 MHz or 27.125 MHz) improved results and reduced the tissue injury caused by galvanic electrolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2,29\">",
"     2,29",
"    </a>",
"    ]. Thermolytic electrolysis creates heat at the needle tip destroying the follicle. It is much more rapid, and as a result, electrolysis now typically involves either thermolytic electrolysis or a combination of galvanic and thermolytic electrolysis referred to as \"the blend\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrolysis can be effective in reducing hair counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/6\">",
"     6",
"    </a>",
"    ]. There are no controlled clinical trials comparing each method although the theory behind electrolysis implies permanence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/31\">",
"     31",
"    </a>",
"    ]. In the best hands, many patients have permanent hair removal with 15 to 25 percent regrowth at the end of six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2,29\">",
"     2,29",
"    </a>",
"    ]. Given the overall slower nature of the procedure, it is better suited for relatively small areas, though one could, with regular sessions over a long period, remove hair from larger areas.",
"   </p>",
"   <p>",
"    Electrolysis can be painful. Topical anesthetic creams such as EMLA (Eutetic Mixture of Local Anesthetics;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/25/32150?source=see_link\">",
"     lidocaine-prilocaine",
"    </a>",
"    ) or LMX (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    cream) may be helpful in reducing pain when electrolysis is performed in sensitive areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Electrolysis can cause erythema and postinflammatory pigment changes; it involves tissue destruction, and scarring is possible. It is felt that patients with pacemakers should not undergo electrolysis, as the electrical field generated by thermolysis and direct current through the body could interfere with pacing and possibly cause the device to fail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2,5,29\">",
"     2,5,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrolysis, like any injury, may promote a flare of topical herpes simplex virus (HSV). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .) Patients with recurrent HSV may want to consider antiviral prophylaxis when treated with electrolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perhaps the biggest drawback of electrolysis is the lack of standard regulations governing its practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/28\">",
"     28",
"    </a>",
"    ]. The laws regulating electrolysis vary from state to state. Many states require no training before one sets up practice. In the best hands, the method can produce permanent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2,28,29\">",
"     2,28,29",
"    </a>",
"    ]. However, there is a great deal of variability in skill as a result of nonstandard regulations and the different types of equipment used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for removal of unwanted hair include methods that temporarily remove hair (plucking, waxing, shaving, chemical depilatories, and pharmacologic methods) and methods that may be able to permanently remove hair (electrolysis and",
"    <span class=\"nowrap\">",
"     laser/light",
"    </span>",
"    treatments). Decisions among these options involve patient preferences, tolerance of discomfort and pain, risks of complications, and cost. In general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plucking hairs can temporarily remove hair for six to eight weeks, may be uncomfortable, and is best suited to small numbers of hairs, such as on selected areas of the face.",
"     </li>",
"     <li>",
"      Waxing accomplishes the same effect as plucking. If it is well tolerated, like plucking it can be used on small numbers of hairs (eg, face) and can also be used for small or delicate areas (eg, bikini area). Unlike plucking, it may also be appropriate for larger numbers of hairs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hair removal over a wider area (eg, back, legs).",
"     </li>",
"     <li>",
"      Chemical depilatories can painlessly remove hair, but they may cause irritation and may have an unpleasant odor. They can be used on virtually any body area as long as there are no significant problems with side effects such as irritation.",
"     </li>",
"     <li>",
"      Shaving is generally safe, but it can produce skin irritation and must be repeated frequently. Repeated shaving does not cause hair to thicken. Shaving can be used on any body area.",
"     </li>",
"     <li>",
"      Laser therapy and intense pulsed light may also remove hair, but do not always result in complete permanent removal. Some patients may require periodic maintenance treatments.",
"      <span class=\"nowrap\">",
"       Laser/light",
"      </span>",
"      hair removal is highly effective for small areas (eg, face, bikini area) or large areas such as the arms, legs, chest, and back. Pigmentary changes are uncommon side effects and scarring is rare.",
"     </li>",
"     <li>",
"      Electrolysis can permanently remove hair when done correctly, but it is a slow process that can be uncomfortable and can occasionally cause scarring. Electrolysis is typically used on selected areas of the face (eg, eyebrows, chin, upper lip), but it can also be used in the bikini area and other small areas.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"       Eflornithine",
"      </a>",
"      cream can reduce amounts of unwanted facial hair in women, but it takes six to eight weeks to be effective, and the hair returns within about eight weeks after the cream is stopped. Although approved by the US FDA only for the face, it could theoretically be used in other areas. However, it&rsquo;s expensive and generally not covered by most insurance plans in the United States, which may limit its practicality to smaller areas.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/1\">",
"      Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/2\">",
"      Olsen EA. Methods of hair removal. J Am Acad Dermatol 1999; 40:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/3\">",
"      JOHNSON E, EBLING FJ. THE EFFECT OF PLUCKING HAIRS DURING DIFFERENT PHASES OF THE FOLLICULAR CYCLE. J Embryol Exp Morphol 1964; 12:465.",
"     </a>",
"    </li>",
"    <li>",
"     Taber's cyclopedic medical dictionary, Thomas CL (Ed), F. A. Davis, Philadelphia 1997. p.511, 657.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/5\">",
"      Ramos-e-Silva M, de Castro MC, Carneiro LV Jr. Hair removal. Clin Dermatol 2001; 19:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/6\">",
"      Urushibata O, Kase K. A comparative study of axillar hair removal in women: plucking versus the blend method. J Dermatol 1995; 22:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/7\">",
"      BHAKTAVIZIAM C, MESCON H, MATOLTSY AG. SHAVING. I. STUDY OF SKIN AND SHAVINGS. Arch Dermatol 1963; 88:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/8\">",
"      Lynfield YL, Macwilliams P. Shaving and hair growth. J Invest Dermatol 1970; 55:170.",
"     </a>",
"    </li>",
"    <li>",
"     Barba A. Techniques for hair removal. In: Cosmetic Dermatology, McGraw-Hill, New York 2002. p.188.",
"    </li>",
"    <li>",
"     Vaniqa package insert www.fda.gov/cder/foi/label/2000/21145lbl.pdf (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/11\">",
"      Smith SR, Piacquadio DJ, Beger B, Littler C. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg 2006; 32:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/12\">",
"      Hamzavi I, Tan E, Shapiro J, Lui H. A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol 2007; 57:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/13\">",
"      Hickman JG, Huber F, Palmisano M. Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair. Curr Med Res Opin 2001; 16:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/14\">",
"      Malhotra B, Noveck R, Behr D, Palmisano M. Percutaneous absorption and pharmacokinetics of eflornithine HCl 13.9% cream in women with unwanted facial hair. J Clin Pharmacol 2001; 41:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/15\">",
"      Weiss RA, Weiss MA, Marwaha S, Harrington AC. Hair removal with a non-coherent filtered flashlamp intense pulsed light source. Lasers Surg Med 1999; 24:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/16\">",
"      Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/17\">",
"      Haedersdal M, Wulf HC. Evidence-based review of hair removal using lasers and light sources. J Eur Acad Dermatol Venereol 2006; 20:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/18\">",
"      Goldberg DJ. Laser hair removal. Dermatol Clin 2002; 20:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/19\">",
"      Tse Y. Hair removal using a pulsed-intense light source. Dermatol Clin 1999; 17:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/20\">",
"      Battle EF Jr, Hobbs LM. Laser therapy on darker ethnic skin. Dermatol Clin 2003; 21:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/21\">",
"      Tanzi EL, Lupton JR, Alster TS. Lasers in dermatology: four decades of progress. J Am Acad Dermatol 2003; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/22\">",
"      Hussain M, Polnikorn N, Goldberg DJ. Laser-assisted hair removal in Asian skin: efficacy, complications, and the effect of single versus multiple treatments. Dermatol Surg 2003; 29:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/23\">",
"      Liew SH, Grobbelaar AO, Gault D, et al. Ruby laser-assisted hair removal: a preliminary report of the correlation between efficacy of treatment and melanin content of hair and the growth phases of hair at a specific site. Ann Plast Surg 1999; 42:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/24\">",
"      McBurney EI. Side effects and complications of laser therapy. Dermatol Clin 2002; 20:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/25\">",
"      Lapidoth M, Shafirstein G, Ben Amitai D, et al. Reticulate erythema following diode laser-assisted hair removal: a new side effect of a common procedure. J Am Acad Dermatol 2004; 51:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/26\">",
"      Alajlan A, Shapiro J, Rivers JK, et al. Paradoxical hypertrichosis after laser epilation. J Am Acad Dermatol 2005; 53:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/27\">",
"      Kontoes P, Vlachos S, Konstantinos M, et al. Hair induction after laser-assisted hair removal and its treatment. J Am Acad Dermatol 2006; 54:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/28\">",
"      Michel CE. Trichiasis and districhiasis; reflections upon their nature and pathology, with a radical method of treatment. St. Louis Cour Med 1879; 1:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/29\">",
"      Wagner RF Jr, Tomich JM, Grande DJ. Electrolysis and thermolysis for permanent hair removal. J Am Acad Dermatol 1985; 12:441.",
"     </a>",
"    </li>",
"    <li>",
"     Hinkel AR, Lind RW. Electrolysis, thermolysis and the blend: The principles and practice of permanent hair removal, Arroway, Los Angeles 1968.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/31\">",
"      Kligman AM, Peters L. Histologic changes of human hair follicles after electrolysis: a comparison of two methods. Cutis 1984; 34:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/32\">",
"      Wagner RF Jr, Flores CA, Argo LF. A double-blind placebo controlled study of a 5% lidocaine/prilocaine cream (EMLA) for topical anesthesia during thermolysis. J Dermatol Surg Oncol 1994; 20:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37014/abstract/33\">",
"      Guardiano RA, Norwood CW. Direct comparison of EMLA versus lidocaine for pain control in Nd:YAG 1,064 nm laser hair removal. Dermatol Surg 2005; 31:396.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1589 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37014=[""].join("\n");
var outline_f36_9_37014=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HAIR GROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REMOVAL OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Temporary methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Plucking/epilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Waxing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Depilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Shaving",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bleaching",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pharmacologic options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laser and intense pulsed light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Electrolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/1589\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1589|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/37/36443\" title=\"table 1\">",
"      Modalities photoepilation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=related_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=related_link\">",
"      Folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13846?source=related_link\">",
"      Nonscarring hair loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/28/24007?source=related_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36343?source=related_link\">",
"      Pseudofolliculitis barbae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35416?source=related_link\">",
"      Treatment of hirsutism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_9_37015="Transtracheal oxygen therapy";
var content_f36_9_37015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transtracheal oxygen therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37015/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37015/contributors\">",
"     Michael D Schwartz, MD, FACP, FCCP, FCCM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37015/contributors\">",
"     Kent L Christopher, MD, RRT, FCCP, FAARC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37015/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37015/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37015/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37015/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37015/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/9/37015/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transtracheal oxygen (TTO) therapy refers to the delivery of long-term oxygen therapy (LTOT) through a transtracheal catheter (",
"    <a class=\"graphic graphic_picture graphicRef77845 \" href=\"mobipreview.htm?10/11/10417\">",
"     picture 1",
"    </a>",
"    ). It is an alternative to conventional LTOT, which is delivered through a nasal cannula.",
"   </p>",
"   <p>",
"    The benefits of TTO therapy, patient selection, complications, and reimbursement are discussed in this topic review. Other issues related to LTOT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21927?source=see_link\">",
"     \"Oxygen conserving devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTO therapy offers several potential benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/1\">",
"     1",
"    </a>",
"    ]. Most studies that have examined the efficacy of TTO have used the subject as his or her own control. In the short-term physiologic studies, patients with an existing transtracheocutaneous fistula usually received interventions related to tracheal gas delivery in a random order, then were compared to controls with no tracheal flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the long-term clinical studies, data collected after initiation of TTO therapy were compared to data collected while the patient was receiving LTOT by nasal cannula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. One trial randomized 43 patients to receive TTO or LTOT via nasal cannula for the duration of the trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TTO was found to have the following effects when compared to LTOT delivered via nasal cannula (",
"    <a class=\"graphic graphic_table graphicRef60760 \" href=\"mobipreview.htm?10/51/11068\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduces the oxygen flow that is required to achieve the same arterial oxyhemoglobin saturation, both at rest (55 percent reduction) and during exercise (30 percent reduction) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improved exercise capacity was observed in two studies; however a third study found no increase in exercise capacity with TTO compared to nasal cannula, when controlled for oxygen saturation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/3,5,9\">",
"       3,5,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improves the room air alveolar to arterial oxygen tension gradient (ie, A-a gradient) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/6,9\">",
"       6,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduces erythrocytosis and improves cor pulmonale [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/4,7,9\">",
"       4,7,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduces or maintains arterial carbon dioxide tension (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Corrects hypoxemia that was refractory to LTOT delivered by nasal cannula [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improves activity and mobility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improves physical, social, and psychological function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improves compliance (daily duration of oxygen use) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduces days of hospitalization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transtracheal flow (of air or oxygen) also has physiologic advantages compared to breathing without transtracheal flow (",
"    <a class=\"graphic graphic_table graphicRef76455 \" href=\"mobipreview.htm?11/20/11595\">",
"     table 2",
"    </a>",
"    ). Specifically, transtracheal gas delivery reduces inspired minute volume, dead space volume, and tidal volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/2,10-12\">",
"     2,10-12",
"    </a>",
"    ]. It also shortens the time of inspiration and decreases the work of breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/10\">",
"     10",
"    </a>",
"    ]. Higher tracheal flows produce greater benefit than lower flows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anecdotal benefits have also been attributed to TTO therapy. These include reduced dyspnea, greater comfort, elimination of nasal cannula complications, and improved self image [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TTO therapy increases the number of hours per day that supplemental oxygen is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. Increased compliance with oxygen therapy has been shown to improve survival; however, the effect of TTO on survival has not been studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTO therapy is most appropriate for patients with chronic hypoxemia who require a low oxygen flow rate and are in an early stage of their illness, because such individuals are most likely to experience improved quality of life for many years. Benefit is less likely and complications are more common when TTO therapy is initiated in patients who require high flow rates during a preterminal phase of their illness (",
"    <a class=\"graphic graphic_table graphicRef58434 \" href=\"mobipreview.htm?37/60/38859\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]. However, even patients with advanced disease may still derive considerable benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/7,16,17\">",
"     7,16,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Benefits'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Indications for the need for supplemental oxygen in general are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for TTO therapy include (",
"    <a class=\"graphic graphic_table graphicRef60760 \" href=\"mobipreview.htm?10/51/11068\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient preference",
"     </li>",
"     <li>",
"      The need for any of the benefits described above, such as reduced dyspnea, improved exercise capacity, or improved mobility (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Benefits'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Complications of LTOT delivered by nasal cannula, especially if the complications impact compliance, such as frequent epistaxis",
"     </li>",
"     <li>",
"      Despite LTOT via nasal cannula, the patient has cor pulmonale, erythrocytosis, or nocturnal hypoxemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who required LTOT prior to an episode of respiratory failure requiring tracheostomy for mechanical ventilation, consideration may be given to decannulation to TTO when they wean from mechanical ventilation; this will avoid the risks of a procedure to create a tracheocutaneous fistula.",
"   </p>",
"   <p>",
"    TTO therapy can be initiated as an intervention of last resort in patients who have hypoxemia that is refractory to LTOT via nasal cannula. However, the risks versus the benefits of TTO therapy in this situation should be carefully weighed and discussed with the patient because such patients are more likely to experience a complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTO therapy should not be offered to patients who are in acute respiratory distress, medically unstable, or have unsuitable anatomy, such as a severe upper airway obstruction or pleura herniated into the site selected for creation of the tracheocutaneous fistula. It also should not be initiated in patients who cannot consistently perform their own catheter care, are noncompliant with medical care, or have a severe anxiety disorder (",
"    <a class=\"graphic graphic_table graphicRef73278 \" href=\"mobipreview.htm?5/48/5900\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some patient characteristics do not preclude TTO therapy, but may predispose an individual to complications and should be carefully considered when determining whether a patient is appropriate for TTO therapy. They include poor pulmonary reserve, obese neck or other anatomical challenges, mild to moderate anxiety, bronchial hyperreactivity, copious or unusually viscous sputum, bleeding disorder, or poor healing. Management of medications that increase bleeding risk would be that same as for any other interventional procedure or surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTO therapy is usually coordinated by a team that consists of a clinician and a respiratory care practitioner (respiratory therapist) or nurse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/13\">",
"     13",
"    </a>",
"    ]. Close communication among the clinicians, nurses, and respiratory care practitioners comprising the TTO team is central to the success of a TTO program.",
"   </p>",
"   <p>",
"    Centers with more experience report fewer technical problems, which suggests that there is a learning curve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/8,18\">",
"     8,18",
"    </a>",
"    ]. Thus, it is advisable that institutions introduce TTO in a graduated fashion, starting with ideal candidates and progressing to more difficult patients once there is more substantial institutional experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once it has been determined that TTO therapy is appropriate, it is usually initiated using the Spofford Christopher Oxygen Optimizing Program (SCOOP), which consists of four distinct phases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/1,13,15,19-21\">",
"     1,13,15,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Phase I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase I involves preparation for creation of a tracheocutaneous fistula, in which the transtracheal catheter will reside (",
"    <a class=\"graphic graphic_table graphicRef63083 \" href=\"mobipreview.htm?8/31/8699\">",
"     table 5",
"    </a>",
"    ). This consists of a preprocedure evaluation and patient education.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Preprocedure evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should undergo a preprocedure evaluation that is aimed at optimizing baseline pulmonary status and identifying and excluding poor candidates for tracheocutaneous fistula creation (",
"    <a class=\"graphic graphic_table graphicRef58434 \" href=\"mobipreview.htm?37/60/38859\">",
"     table 3",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef73278 \" href=\"mobipreview.htm?5/48/5900\">",
"     table 4",
"    </a>",
"    ). The procedure should be delayed if the patient is unstable or their condition could be better optimized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/13\">",
"     13",
"    </a>",
"    ]. The evaluation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A directed history and physical examination should be performed to identify any new or increased symptoms (eg, increased sputum) or signs (eg, wheezing) that indicate that the patient's medical condition is not optimized. Neck anatomy is assessed to make sure tracheal interspaces are easily identifiable (",
"      <a class=\"graphic graphic_figure graphicRef76129 \" href=\"mobipreview.htm?22/58/23456\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A chest radiograph is necessary to exclude patients with anatomic contraindications or challenges to the procedure, such as pleura herniated into the site selected for creation of the tracheocutaneous fistula or a deviated trachea.",
"     </li>",
"     <li>",
"      Spirometry with measurement of the FEV1 pre- and post-bronchodilator should be performed to evaluate ventilatory reserve and assess risk for bronchospasm. We typically perform spirometry within one week of the procedure; we delay the procedure and intensify the medical regimen, if FEV1 is less than 500 mL or is less than 70 percent of that patient's baseline (if baseline data are available) or increases more than 12 percent following inhaled bronchodilator. Patients prone to bronchospasm should be monitored more closely through all steps, especially during initial catheter changes.",
"     </li>",
"     <li>",
"      Arterial blood gases should be reviewed to determine the severity of the hypoxemia (ie, the arterial oxygen tension, PaO",
"      <sub>",
"       2",
"      </sub>",
"      ) and the ventilatory impairment (ie, the pH and arterial carbon dioxide tension, PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ). These values are useful in confirming the need for supplemental oxygen therapy, assessing clinical stability, and determining the likelihood that a patient will benefit from TTO. The severity of ventilatory impairment (reduced FEV1 or hypercarbia) that precludes TTO is determined on a case-by-case basis after carefully weighing the importance of the potential benefits, the experience of the care team, and the risks of the procedure (",
"      <a class=\"graphic graphic_table graphicRef73278 \" href=\"mobipreview.htm?5/48/5900\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive teaching is important because patients must be able to reliably care for the catheter and recognize potential complications. Ideally, patients should view a training video, receive an educational booklet, participate in a question and answer session with a staff member, and speak to a patient who is using transtracheal oxygen&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/13,15,19,20\">",
"     13,15,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Phase II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase II involves creation of the tracheocutaneous fistula (",
"    <a class=\"graphic graphic_table graphicRef74858 \" href=\"mobipreview.htm?32/45/33499\">",
"     table 6",
"    </a>",
"    ). Two techniques are available, the modified Seldinger technique (MST) and the Lipkin procedure. We prefer the Lipkin procedure for the reasons described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Modified Seldinger technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modified Seldinger technique (MST) refers to the use of an introducer needle, followed by a guidewire over which a catheter is passed. A detailed discussion is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/13\">",
"     13",
"    </a>",
"    ]. The following is an overview of the technique for creating a transcutaneous fistula:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carefully identify the first or second tracheal interspace (",
"      <a class=\"graphic graphic_figure graphicRef76129 \" href=\"mobipreview.htm?22/58/23456\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administer a local anesthetic (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      1 or 2 percent, about 3 to 5 mL)",
"     </li>",
"     <li>",
"      Prepare the site with 10 percent povidone-iodine solution or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      and drape the area with sterile towels",
"     </li>",
"     <li>",
"      Reidentify the correct tracheal interspace and insert the introducer needle percutaneously with the bevel facing away from the head",
"     </li>",
"     <li>",
"      Thread the matching guidewire through the introducer needle and into the lumen of the trachea and then remove the introducer needle",
"     </li>",
"     <li>",
"      Create the tracheocutaneous fistula by advancing a single dilator over the guidewire with a gentle twisting motion",
"     </li>",
"     <li>",
"      Insert the nonfunctioning stent, remove the guidewire, and suture the stent in place [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prescribe a prophylactic oral antibiotic (effective against streptococcus and staphylococcus), which is typically given for 7 to 14 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nonfunctioning stent remains in position for one week. A guidewire is then threaded through the stent; the stent is removed over the guidewire. A transtracheal catheter is then inserted over the guidewire, which is subsequently removed. TTO therapy can then be initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/13\">",
"     13",
"    </a>",
"    ]. The one week delay reduces the risk of subcutaneous emphysema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Lipkin procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Lipkin procedure (ie, mini-tracheotomy) is a surgical approach to tracheocutaneous fistula creation that avoids some of the shortcomings of the MST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. It is done under moderate sedation (conscious sedation) in the operating room. The procedure requires less than one hour and the patient remains in the hospital under observation until the next day. A general outline of the procedure is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ascertain adequate conscious sedation.",
"     </li>",
"     <li>",
"      Carefully identify the first or second tracheal interspace (",
"      <a class=\"graphic graphic_figure graphicRef76129 \" href=\"mobipreview.htm?22/58/23456\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prepare the site with 10 percent povidone-iodine solution or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      and drape the area with sterile towels.",
"     </li>",
"     <li>",
"      Reidentify the correct tracheal interspace (usually the first or second tracheal interspace) and make a vertical incision at the selected site. Flaps of full-thickness skin are elevated, and cervical fat is removed down to the strap muscles.",
"     </li>",
"     <li>",
"      Separate the strap muscles at the midline, exposing the anterior wall of the trachea.",
"     </li>",
"     <li>",
"      Suture the skin flaps to the undersides of the exposed sternothyroid muscles, thereby forming an epithelialized tract that extends to the anterior wall of the trachea.",
"     </li>",
"     <li>",
"      Make a small horizontal incision between the tracheal cartilage rings, and puncture the trachea at this incision using a device called a tracheal punch (Fast Tract&trade; Procedure Tray, Transtracheal Systems, Inc., Denver, CO USA). The tracheal punch resects a small window of cartilage.",
"     </li>",
"     <li>",
"      Insert a nonfunctioning stent into the tract using a stylette. Oxygen continues to be applied via nasal cannula or mask.",
"     </li>",
"     <li>",
"      Prescribe a prophylactic oral antibiotic (effective against streptococcus and staphylococcus), which is typically given for 7 to 14 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the postoperative period, we typically use judicious amounts of narcotic analgesics, for analgesia and cough suppression. If a narcotic is not needed for analgesia, cough can usually be managed with a nonnarcotic cough suppressant or by injecting 1 to 3 mL of 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (without epinephrine) into the stent every four to six hours.",
"   </p>",
"   <p>",
"    The following day, a guidewire is threaded through the stent, the stent is removed, the transtracheal catheter is inserted, and the guidewire is removed leaving only the catheter in position. The catheter is held in position by a bead chain necklace. Placement of clear medical tape over the necklace, just lateral to the catheter on each side, further secures the catheter in position. At this time, the patient can begin to receive TTO therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheocutaneous fistula creation using the MST has several shortcomings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/1\">",
"     1",
"    </a>",
"    ]. The catheter cannot be removed by the patient and thoroughly cleaned until the tract is mature and the patient has been trained to periodically remove and reinsert it. This usually takes about eight weeks. During this time, there is a tendency for mucus to adhere to the tip of the catheter and accumulate (ie, form a mucus ball), which can cause upper airway obstruction and respiratory deterioration. The care team must periodically remove the catheter over a guidewire to clean it. In addition, the tracheocutaneous fistula can close (ie, lost tract) if the catheter is dislodged. Chondritis and chronic tract inflammation can develop in tracheal cartilage inadvertently exposed or injured during the procedure, which may also stimulate keloid formation in predisposed individuals. All of these adverse sequelae can compromise the tracheocutaneous fistula, making catheter insertion difficult.",
"   </p>",
"   <p>",
"    Observational studies suggest that the Lipkin procedure is well tolerated and has a number of benefits compared to the MST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a review of 33 Lipkin procedures compared with 64 historical controls who underwent MST, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tracheocutaneous fistula created by the Lipkin procedure matured faster than that created by the MST (two versus eight weeks).",
"     </li>",
"     <li>",
"      Mucus ball formation is lower with the Lipkin procedure (5 to 10 percent) compared with the MST (10 to 15 percent). The rate of tract loss is also lower with the Lipkin procedure.",
"     </li>",
"     <li>",
"      Resection of a window of cartilage reduced the incidence of chondritis (12 versus 25 percent) and keloid formation, which may further reduce the risk of lost tracts.",
"     </li>",
"     <li>",
"      The surgically created tract had fewer instances of subcutaneous emphysema.",
"     </li>",
"     <li>",
"      With the Lipkin procedure, TTO therapy was initiated one day after the procedure, rather than one week.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Phase III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase III involves the initiation of TTO through an immature tracheocutaneous fistula (ie, tract) (",
"    <a class=\"graphic graphic_table graphicRef57966 \" href=\"mobipreview.htm?14/20/14669\">",
"     table 7",
"    </a>",
"    ). The main goals of this phase are to prevent symptomatic mucus balls, prevent tract loss, and monitor tract healing. This phase applies equally to tracts created by either the modified Seldinger technique or the Lipkin procedure.",
"   </p>",
"   <p>",
"    Once the nonfunctioning stent has been replaced with a transtracheal catheter and secured with a fitted bead chain necklace, TTO therapy can begin. Oxygen flow is titrated to achieve an adequate oxyhemoglobin saturation during rest and exertion, as measured by pulse oximetry. Patients, family members, and caregivers are instructed about catheter care, which includes cleaning the internal lumen of the catheter with instilled saline and a cleaning rod at least twice daily. Patients should return two to three times over the next two weeks to reinforce education, evaluate tract maturity, and strip mucus from the outside of the catheter.",
"   </p>",
"   <p>",
"    Normal sequelae encountered during the first few days include mild tenderness at the insertion site, scant hemoptysis, or a transient increase in cough and sputum production. Patients may have an air leak through the stoma for a few days, which can affect speech. Gentle pressure on the stoma makes phonation easier if this occurs.",
"   </p>",
"   <p>",
"    The convention has been to administer TTO with a continuous flow of oxygen. Pulse or demand oxygen delivery systems (DODS) that require one lumen for delivery and a separate lumen for sensing inspiratory effort are not compatible with the single lumen TTO catheter. As a result, specific DODS designs utilizing alternating sensing and delivery through a single lumen have been assessed in terms of adequacy of oxyhemoglobin saturation and oxygen savings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, it does not appear that DODS adds substantially to oxygen conservation achieved with TTO alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21927?source=see_link\">",
"     \"Oxygen conserving devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Tract loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dislodgement of the transtracheal catheter can result in tract loss. To minimize the likelihood of tract loss, patients should be instructed about what to do if inadvertent dislodgement of the transtracheal catheter occurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Return to nasal cannula oxygen",
"     </li>",
"     <li>",
"      Clean the catheter and lubricate it with sterile, water soluble jelly",
"     </li>",
"     <li>",
"      Gently attempt reinsertion",
"     </li>",
"     <li>",
"      Assistance should be sought from the TTO team if reinsertion is not successful after two attempts",
"     </li>",
"     <li>",
"      If the team is also unsuccessful, it may be possible to insert a guide wire and then the catheter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple reinsertion attempts are not advised, because this can create a false tract, with misplacement of the catheter pre- or paratracheally into the anterior mediastinum. Repeat tract creation can be considered if the tract cannot be recovered. The Lipkin procedure has a much lower rate of tract loss, compared to the MST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mucus accumulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucus can accumulate around the distal tip of the catheter and form a mucus ball, which may be large enough to cause upper airway obstruction and respiratory deterioration. To prevent this, patients should be instructed about minimizing mucus accumulation and recognizing mucus accumulation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measures to minimize mucus accumulation include adequate humidification of supplemental oxygen, frequent cleaning of the transtracheal catheter, adequate systemic hydration, and administration of a mucokinetic agent. We typically prescribe",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16101?source=see_link\">",
"       guaifenesin",
"      </a>",
"      600 to 1200 mg orally twice a day. In addition, for patients with COPD who are not on inhaled glucocorticoid therapy, we often add an inhaled glucocorticoid to decrease mucus production.",
"     </li>",
"     <li>",
"      Early recognition of mucus accumulation is facilitated by frequent monitoring by telephone, frequent follow-up visits, and patient education about symptoms that suggest mucus ball accumulation (eg, increased or severe cough, dyspnea, or wheezing).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a low FEV1 and weak cough may require more frequent catheter stripping because they are less likely to be able to expel accumulating mucus. Similarly, individuals requiring high TTO flows and those with copious or tenacious sputum are predisposed to mucus balls. Catheter stripping refers to removal of the catheter from the tract over a guidewire by the team, during which most of the mucus that has accumulated around the distal tip of the catheter will be scraped off by the removal process, and subsequently expelled by cough. Mucus that remains on the catheter can be manually removed during cleaning and then the catheter must be promptly reinserted over the guidewire.",
"   </p>",
"   <p>",
"    Mucus ball accumulation is most common in Phase III, but can occur after years of uneventful TTO therapy. Approximately 10 to 15 percent of patients experience symptomatic mucus balls when the MST procedure is used, compared with 5 to 10 percent with the Lipkin procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Phase IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase IV involves the maintenance of TTO therapy through a mature tract, which is defined as a tract through which the catheter easily slips into position (",
"    <a class=\"graphic graphic_table graphicRef65577 \" href=\"mobipreview.htm?5/24/5516\">",
"     table 8",
"    </a>",
"    ). The goal of this phase is for the patient to avoid complications through self care.",
"   </p>",
"   <p>",
"    During Phase IV, a cleaning protocol should be customized to patient needs. Cleaning protocols can utilize cleaning the catheter while it is in position (as in Phase III) and cleaning the catheter once it has been removed. The removed catheter is replaced by a previously cleaned second catheter in an alternating fashion. The protocol can be adjusted according to symptoms. The majority of patients remove the catheter for cleaning twice per day to prevent mucus accumulation. Others do well with cleaning in place twice daily on most days, with removal for cleaning once or twice per week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     GENERAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most complications are not life-threatening. These include subcutaneous emphysema, bronchospasm, hemoptysis, mucus collection, lost tracts, chondritis, and infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/1,4,5,8,18,26,27\">",
"     1,4,5,8,18,26,27",
"    </a>",
"    ]. One small case series described frequent lower respiratory tract infections that required hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/28\">",
"     28",
"    </a>",
"    ]. All of the patients in this report had severe interstitial lung disease and required a high oxygen flow rate.",
"   </p>",
"   <p>",
"    Life-threatening complications have been described in case reports. These complications include airway obstruction from a massive mucus ball, extratracheal misplacement of the catheter, and pneumothorax with pneumomediastinum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37015/abstract/29-36\">",
"     29-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transtracheal oxygen (TTO) therapy refers to the delivery of long-term oxygen therapy (LTOT) through a transtracheal catheter (",
"      <a class=\"graphic graphic_picture graphicRef77845 \" href=\"mobipreview.htm?10/11/10417\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TTO therapy offers several potential benefits, compared to LTOT delivered by nasal cannula, including reduced dyspnea, improved mobility, improved comfort, increased exercise capacity, and fewer days of hospitalization. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic hypoxemia who require a low oxygen flow rate and are in an early stage of their illness are the most likely to experience improved quality of life when using TTO therapy, compared to LTOT via nasal cannula. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reasons to choose TTO, instead of nasal cannula, include patient preference, reduced oxygen requirement, improved mobility, and avoidance of nasal cannula-related complications (",
"      <a class=\"graphic graphic_table graphicRef60760 \" href=\"mobipreview.htm?10/51/11068\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef76455 \" href=\"mobipreview.htm?11/20/11595\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not initiate TTO therapy in patients who are in acute respiratory distress, medically unstable, or have unsuitable anatomy. It also should not be initiated in patients who cannot consistently perform their own catheter care, are noncompliant with medical care, have severe upper airway obstruction, or have severe anxiety. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TTO therapy is usually initiated using the Spofford Christopher Oxygen Optimizing Program (SCOOP), which consists of four distinct phases (",
"      <a class=\"graphic graphic_table graphicRef63083 \" href=\"mobipreview.htm?8/31/8699\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74858 \" href=\"mobipreview.htm?32/45/33499\">",
"       table 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57966 \" href=\"mobipreview.htm?14/20/14669\">",
"       table 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65577 \" href=\"mobipreview.htm?5/24/5516\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that the tracheocutaneous fistula be created using the Lipkin procedure, rather than the modified Seldinger technique (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Phase II'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most complications of TTO therapy are minor, including subcutaneous emphysema, bronchospasm, hemoptysis, mucus collection, local chondritis, lost tracheocutaneous fistulas, and infections. Life-threatening complications are rare, but have been described. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'General complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DISCLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kent Christopher, MD, has licensed the patents for the SCOOP transtracheal oxygen therapy technology to Transtracheal Systems, Inc. He may receive financial gain from that license in the future. Dr. Christopher presently has no professional relationship with the company. Michael Schwartz, MD, does not have a financial relationship with any entity that has an interest in the subject of this manuscript.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Christopher KL. Transtracheal oxygen therapy. In: Interventional Pulmonary Medicine, Beamis J, Mathur P, Mehta A (Eds), Marcel Dekker, New York 2004. p.503.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/2\">",
"      Bergofsky EH, Hurewitz AN. Airway insufflation: physiologic effects on acute and chronic gas exchange in humans. Am Rev Respir Dis 1989; 140:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/3\">",
"      Dewan NA, Bell CW. Effect of low flow and high flow oxygen delivery on exercise tolerance and sensation of dyspnea. A study comparing the transtracheal catheter and nasal prongs. Chest 1994; 105:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/4\">",
"      Christopher KL, Spofford BT, Petrun MD, et al. A program for transtracheal oxygen delivery. Assessment of safety and efficacy. Ann Intern Med 1987; 107:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/5\">",
"      Hoffman LA, Wesmiller SW, Sciurba FC, et al. Nasal cannula and transtracheal oxygen delivery. A comparison of patient response after 6 months of each technique. Am Rev Respir Dis 1992; 145:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/6\">",
"      O'Donohue WJ Jr. Effect of oxygen therapy on increasing arterial oxygen tension in hypoxemic patients with stable chronic obstructive pulmonary disease while breathing ambient air. Chest 1991; 100:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/7\">",
"      Christopher KL, Spofford BT, Brannin PK, Petty TL. Transtracheal oxygen therapy for refractory hypoxemia. JAMA 1986; 256:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/8\">",
"      Kampelmacher MJ, Deenstra M, van Kesteren RG, et al. Transtracheal oxygen therapy: an effective and safe alternative to nasal oxygen administration. Eur Respir J 1997; 10:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/9\">",
"      Bloom BS, Daniel JM, Wiseman M, et al. Transtracheal oxygen delivery and patients with chronic obstructive pulmonary disease. Respir Med 1989; 83:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/10\">",
"      Benditt J, Pollock M, Roa J, Celli B. Transtracheal delivery of gas decreases the oxygen cost of breathing. Am Rev Respir Dis 1993; 147:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/11\">",
"      Couser JI Jr, Make BJ. Transtracheal oxygen decreases inspired minute ventilation. Am Rev Respir Dis 1989; 139:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/12\">",
"      Hurewitz AN, Bergofsky EH, Vomero E. Airway insufflation. Increasing flow rates progressively reduce dead space in respiratory failure. Am Rev Respir Dis 1991; 144:1229.",
"     </a>",
"    </li>",
"    <li>",
"     Spofford B, Christopher KL, Goodman JR. Transtracheal Oxygen Therapy. In: Problems in Respiratory Care - The Current Status of Oxygen Therapy, Christopher KL (Ed), J.B. Lippincott Company, Philadelphia 1990. p.600.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/14\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/15\">",
"      Reinke, LF, Hoffman, LA. Transtracheal oxygen: Patient management strategies. Respir Care Prac 1992; 5:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/16\">",
"      Christopher KL, VanHooser DT, Jorgenson SJ, et al. Preliminary observations of transtracheal augmented ventilation for chronic severe respiratory disease. Respir Care 2001; 46:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/17\">",
"      Brack T, Senn O, Russi EW, Bloch KE. Transtracheal high-flow insufflation supports spontaneous respiration in chronic respiratory failure. Chest 2005; 127:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/18\">",
"      Hoffman LA, Johnson JT, Wesmiller SW, et al. Transtracheal delivery of oxygen: efficacy and safety for long-term continuous therapy. Ann Otol Rhinol Laryngol 1991; 100:108.",
"     </a>",
"    </li>",
"    <li>",
"     Hoffman LA, Wesmiller SW. Transtracheal oxygen. In: Portable Oxygen Therapy Including Oxygen Conserving Methodology, Tiep BL (Ed), Futura Publishing Co, Mount Kisco, NY 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/20\">",
"      Wesmiller SW, Hoffman LA, Wiseman M. Understanding transtracheal oxygen delivery. Nursing 1989; 19:43.",
"     </a>",
"    </li>",
"    <li>",
"     SCOOP Transtracheal Oxygen Therapy. Clinical Guide for the Fast Tract Insertion Technique. Transtracheal Systems, Inc., Englewood, CO, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/22\">",
"      Lipkin AF, Christopher KL, Diehl S, et al. Otolaryngologist's role in transtracheal oxygen therapy: the minitrach procedure. Otolaryngol Head Neck Surg 1996; 115:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/23\">",
"      Christopher KL, Schwartz MD. Transtracheal oxygen therapy. Chest 2011; 139:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/24\">",
"      Tiep BL, Christopher KL, Spofford BT, et al. Pulsed nasal and transtracheal oxygen delivery. Chest 1990; 97:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/25\">",
"      Yaeger ES, Goodman S, Hoddes E, Christopher KL. Oxygen therapy using pulse and continuous flow with a transtracheal catheter and a nasal cannula. Chest 1994; 106:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/26\">",
"      Orvidas LJ, Kasperbauer JL, Staats BA, Olsen KD. Long-term clinical experience with transtracheal oxygen catheters. Mayo Clin Proc 1998; 73:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/27\">",
"      Heimlich HJ, Carr GC. The micro-trach. A seven-year experience with transtracheal oxygen therapy. Chest 1989; 95:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/28\">",
"      Couser JI Jr, Make BJ. Respiratory tract infection complicating transtracheal oxygen therapy. Chest 1992; 101:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/29\">",
"      Fletcher EC, Nickeson D, Costarangos-Galarza C. Endotracheal mass resulting from a transtracheal oxygen catheter. Chest 1988; 93:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/30\">",
"      Burton GG, Wagshul FA, Henderson D, Kime SW. Fatal airway obstruction caused by a mucous ball from a transtracheal oxygen catheter. Chest 1991; 99:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/31\">",
"      Harrow EM, Oldenburg FA, Lingenfelter MS, Leonard J. Respiratory failure and cor pulmonale associated with tracheal mucoid accumulation from a SCOOP transtracheal oxygen catheter. Chest 1992; 101:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/32\">",
"      Roth BJ, Irvine TW, Liening DA, et al. Acute respiratory compromise resulting from tracheal mucous impaction secondary to a transtracheal oxygen catheter. Chest 1992; 101:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/33\">",
"      de Groot RE, Dik H, de Groot HG, Bakker W. A nearly fatal tracheal obstruction resulting from a transtracheal oxygen catheter. Chest 1993; 104:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/34\">",
"      Ulstad DR, Koppin J. Massive atelectasis with respiratory arrest due to transtracheal oxygen catheter-related mass formation. Chest 1994; 106:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/35\">",
"      Menon AS, Carlin BW, Kaplan PD. Tracheal perforation. A complication associated with transtracheal oxygen therapy. Chest 1993; 104:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37015/abstract/36\">",
"      Kristo DA, Turner JF, Hugler R. Transtracheal oxygen catheterization with pneumomediastinum and sudden death. Chest 1996; 110:844.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1451 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37015=[""].join("\n");
var outline_f36_9_37015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Phase I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Preprocedure evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Phase II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Modified Seldinger technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Lipkin procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Phase III",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Tract loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mucus accumulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Phase IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      GENERAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DISCLOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1451|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/58/23456\" title=\"figure 1\">",
"      Tracheal anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1451|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/11/10417\" title=\"picture 1\">",
"      TTO2 patient photo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1451|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/51/11068\" title=\"table 1\">",
"      Indications TTO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/20/11595\" title=\"table 2\">",
"      Benefits transtracheal O2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/60/38859\" title=\"table 3\">",
"      Evaluation for transtracheal O2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/48/5900\" title=\"table 4\">",
"      Contraindications TTO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/31/8699\" title=\"table 5\">",
"      Use of SCOOP system I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/45/33499\" title=\"table 6\">",
"      Use of SCOOP system II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/20/14669\" title=\"table 7\">",
"      Use of SCOOP system III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/24/5516\" title=\"table 8\">",
"      Use of SCOOP system IV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21927?source=related_link\">",
"      Oxygen conserving devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_9_37016="XDR TB countries 2010";
var content_f36_9_37016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Countries that reported at least one case of extensively drug resistant tuberculosis by end 2010",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 564px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization. Available at:",
"     <a href=\"file://www.who.int/tb/challenges/xdr/en/index.html\" target=\"_blank\">",
"      file://www.who.int/tb/challenges/xdr/en/index.html",
"     </a>",
"     . Copyright &copy; 2011 WHO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37016=[""].join("\n");
var outline_f36_9_37016=null;
var title_f36_9_37017="Pathogenesis, clinical manifestations, and treatment of early syphilis";
var content_f36_9_37017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical manifestations, and treatment of early syphilis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37017/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37017/contributors\">",
"     Charles B Hicks, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37017/contributors\">",
"     P Frederick Sparling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37017/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37017/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37017/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37017/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/9/37017/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis is a chronic infection caused by the bacterium Treponema pallidum. The manifestations of disease are notoriously protean, occurring in any one individual in different stages over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical manifestations, diagnosis, and therapy of early syphilis will be reviewed here. Late syphilis and the pathophysiology, natural history, and serologic diagnosis of syphilis are discussed separately. Syphilis in the HIV-infected patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Early syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early syphilis is defined as the stages of syphilis (primary, secondary, and early latent syphilis) that typically occur within the first year after acquisition of the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Latent syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Latent syphilis is characterized by asymptomatic infection with a normal physical examination in association with a positive serology. Latent syphilis is categorized as \"early\" or \"late\" depending on the established date of infection. Early latent syphilis infers infection within one year. All other cases are referred to as late latent syphilis or latent syphilis of unknown duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of correct classification is related to the risk of transmission and duration of treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Public health agencies focus their contact tracing efforts on patients with early latent syphilis, since transmission is unlikely in late latency. The emphasis on identifying patients with early syphilis is also based on the concern that lesions may have been present earlier in the year, when sex partners may have been exposed. There is also the risk of recurrent lesions in the index patient, and therefore transmission, if untreated.",
"     </li>",
"     <li>",
"      The USPHS recommends a longer duration of therapy for patients with late latent syphilis. This recommendation is based upon the notion that the biology of the spirochete evolves over time. In late latent syphilis, T. pallidum is thought to have a slower metabolism and a more prolonged dividing time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, misclassification of latent syphilis is common and can have a negative impact on appropriate treatment duration and on contact tracing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Alternatively, some researchers have suggested that latent syphilis should be classified as \"high-titer\" or \"low-titer\" syphilis (based upon VDRL or RPR testing), since high nontreponemal titers are strongly associated with recent infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. However, early latent syphilis cannot be reliably distinguished from late latent syphilis solely on the basis of nontreponemal titers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early syphilis is a reportable infection in the United States, so there are relatively accurate statistics on the incidence of new infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]. In the late 1980s and early 1990s there was a mini-epidemic of early syphilis that ultimately produced case rates that were higher than at any time since the introduction of penicillin. The number of cases peaked in 1990 (20.3 cases per 100,000 population) but subsequently fell to a new all time low in 2000, raising hopes for eradication (",
"    <a class=\"graphic graphic_figure graphicRef59772 \" href=\"mobipreview.htm?30/12/30925\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the Centers for Disease Control and Prevention (CDC) showed that the number of cases of early syphilis increased in 2001 for the first time since 1990, and this trend continued until 2010, when overall rates of primary and secondary syphilis decreased for the first time in a decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/8\">",
"     8",
"    </a>",
"    ]. However, this decline in overall incidence is mainly attributable to a significant decrease in syphilis cases among women (27 percent) while rates among men increased by 1 percent from 2009 to 2010. Rates among men were highest among those aged 20 to 24 years, which is a marked shift from 2005, when rates were highest among men aged 35 to 39 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of syphilis continue to be significantly higher in non-Hispanic blacks compared with non-Hispanic whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In particular, rates among black and Hispanic men aged 20 to 24 years were 15 times and 3 times the rate among white men of the same age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Syphilis remains an important problem in other areas of the world. The World Health Organization estimated that, in 1999, there were 100,000 new cases of syphilis in adults in North America, 140,000 in western Europe, 100,000 in eastern Europe, and central Asia, 370,000 in north Africa and the Middle East, and three to four million each in Latin America and the Caribbean, sub-Saharan Africa, and south and southeast Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/10\">",
"     10",
"    </a>",
"    ]. In China, a national surveillance program demonstrated that after the virtual eradication of syphilis in the 1960s to the 1980s, syphilis has reemerged with a total of 74,000 cases of primary and secondary syphilis diagnosed in 2005 alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Syphilis is associated with an increased risk for HIV acquisition and transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Men who have sex with men'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Women and minority groups'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Men who have sex with men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analyses of data from 2010 demonstrate that most cases of primary and secondary syphilis occur among MSM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/8\">",
"     8",
"    </a>",
"    ]. Risk factors for acquisition of early syphilis among MSM include HIV infection, combination methamphetamine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    use, and having acquired recent sexual partners from the Internet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a relatively high rate of HIV coinfection in persons with syphilis. Among the 6862 cases of primary and secondary syphilis documented in 2002 by the CDC, 25 percent occurred in persons coinfected with HIV; the risk group with the highest incidence rates was HIV-infected MSM (336 cases per 100,000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Women and minority groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, the incidence of early syphilis in women in the United States declined by 35 percent between 2000 and 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/15\">",
"     15",
"    </a>",
"    ], a trend that unfortunately did not continue. Between 2005 and 2009, the number of cases of primary and secondary syphilis in women increased from 1339 to 2232. However, a 2010 report from the CDC demonstrated that rates of syphilis declined by 27 percent among women while rates continued to increase among men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/8\">",
"     8",
"    </a>",
"    ]. Unfortunately, reductions in rates of syphilis noted in African Americans earlier in the decade have not been sustained. During 2006 to 2010, rates among black men aged 20 to 24 years increased 134 percent; the magnitude of this rate increase (53 cases per 100,000 population) was the greatest of any sex, age group, or",
"    <span class=\"nowrap\">",
"     race/ethnicity",
"    </span>",
"    group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of Treponema pallidum usually occurs via direct contact with an infectious lesion during sex. It is thought that the spirochete gains access via disrupted epithelium at sites of minor trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/16\">",
"     16",
"    </a>",
"    ]. The early lesions of primary and secondary syphilis including chancres, mucous patches, and condyloma lata, are very infectious. It has been estimated that transmission occurs in approximately one-third of patients exposed to these lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Syphilis can also be spread by kissing or touching a person who has active lesions on the lips, oral cavity, breasts, or genitals. Transmission of syphilis has been identified in MSM who have reported oral sex as their only risk factor for acquisition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acquisition of syphilis through transfused blood is very rare because all donors are screened and T. pallidum cannot survive longer than 24 to 48 hours under the current blood bank storage conditions. The infection can also be acquired by passage through the placenta. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link\">",
"     \"Syphilis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Incubating syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median incubation period before clinical manifestations is 21 days (range 3 to 90 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Primary syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A description of the pathophysiologic events occurring after acquisition of T. pallidum is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    .) Briefly, after an average incubation period of two to three weeks, a papule, which is typically painless, appears at the site of inoculation. This soon ulcerates to produce the classic chancre of primary syphilis, a one to two centimeter ulcer with a raised, indurated margin (",
"    <a class=\"graphic graphic_picture graphicRef75291 \" href=\"mobipreview.htm?17/16/17664\">",
"     picture 1",
"    </a>",
"    ). The ulcer generally has a non-exudative base and is associated with mild to moderate regional lymphadenopathy that is often bilateral.",
"   </p>",
"   <p>",
"    Such lesions usually occur on the genitalia, but occasionally patients may develop chancres at other sites of inoculation. These sites may include areas that may not be noticeable to the patient, including the posterior pharynx, anus, or vagina. Multiple chancres can occur infrequently, particularly in the setting of HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chancres heal spontaneously within three to six weeks even in the absence of treatment. Since the ulcer is painless, many patients do not seek medical attention, a feature that enhances the likelihood of transmission. The mechanism of healing is unknown, but is thought to be a consequence of local immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the chancre represents initial local infection with T. pallidum, widespread dissemination of the spirochete also occurs early during the primary stage of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Secondary syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weeks to a few months later, approximately 25 percent of individuals with untreated infection will develop a systemic illness that represents secondary syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with secondary syphilis may not have a history of a preceding chancre since the primary lesion may go unnoticed. Secondary syphilis can also develop even when the primary chancre is still present; this may be more commonly seen in the HIV-infected patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary syphilis can produce a wide variety of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rash is the most characteristic finding of secondary syphilis and can take any form, except vesicular lesions. The rash is classically a diffuse, symmetric macular or papular eruption involving the entire trunk and extremities (",
"    <a class=\"graphic graphic_picture graphicRef60313 \" href=\"mobipreview.htm?12/22/12642\">",
"     picture 2",
"    </a>",
"    ), including the palms and soles (",
"    <a class=\"graphic graphic_picture graphicRef79451 \" href=\"mobipreview.htm?15/13/15583\">",
"     picture 3",
"    </a>",
"    ) although localized lesions can also occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/19\">",
"     19",
"    </a>",
"    ]. Individual lesions are discrete red or reddish-brown and measure 0.5 to 2 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef68877 \" href=\"mobipreview.htm?9/3/9279\">",
"     picture 4",
"    </a>",
"    ). They are often scaly but may be smooth and rarely pustular (eg, \"pustular syphilids\"). Pustular syphilis can take the form of small pustular syphilide, large pustular syphilide, flat pustular syphiloderm, and pustular-ulcerative syphilide (ie, malignant syphilis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/19\">",
"     19",
"    </a>",
"    ]. Nodular lesions also may be seen. The involvement of the palms and soles is an important clue to the diagnosis of secondary syphilis.",
"   </p>",
"   <p>",
"    Large, raised, gray to white lesions, involving warm, moist areas such as mucous membranes in the mouth and perineum, may develop in some patients during secondary syphilis. These are referred to as condyloma lata (",
"    <a class=\"graphic graphic_picture graphicRef66087 \" href=\"mobipreview.htm?42/15/43251\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63924 \" href=\"mobipreview.htm?26/12/26818\">",
"     picture 6",
"    </a>",
"    ). These lesions occur most often in areas proximate to the primary chancre and may reflect direct spread of organisms from the primary ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Systemic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic symptoms include fever, headache, malaise, anorexia, sore throat, myalgias, and weight loss. These clinical manifestations probably reflect the brisk immunologic response resulting from widespread dissemination of T. pallidum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with secondary syphilis have lymph node enlargement with palpable nodes present in the posterior cervical, axillary, inguinal and femoral regions (",
"    <a class=\"graphic graphic_picture graphicRef59275 \" href=\"mobipreview.htm?40/45/41695\">",
"     picture 7",
"    </a>",
"    ). The finding of epitrochlear nodes is particularly suggestive of the diagnosis. These nodes are generally minimally tender, firm, and rubbery in consistency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;So-called \"moth-eaten\" alopecia is occasionally seen among patients presenting with secondary syphilis (",
"    <a class=\"graphic graphic_picture graphicRef52213 \" href=\"mobipreview.htm?32/57/33683\">",
"     picture 8",
"    </a>",
"    ). This may be noted on the scalp, eyebrows, or beard, but is usually reversible with treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilitis hepatitis is characterized by a high serum alkaline phosphatase level on laboratory examination, often with normal or only slightly abnormal transaminases. Mild clinical hepatitis resolves with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Gastrointestinal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal tract may become extensively infiltrated or ulcerated; this can be misdiagnosed as lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Musculoskeletal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovitis, osteitis, and periostitis can also occur, but usually resolve after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Renal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with syphilis can have mild transient albuminuria, nephrotic syndrome, or acute nephritis with hypertension and acute renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/23\">",
"     23",
"    </a>",
"    ]. Pathologically, membranous glomerulonephritis or diffuse endocapillary glomerulonephritis, sometimes with crescents, can be seen. Resolution of renal abnormalities follows treatment for syphilis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Neurologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasion of the cerebrospinal fluid (CSF) is common in early stages of the untreated disease. The pathogenesis of CNS syphilis and both its early and late clinical manifestations are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=see_link\">",
"     \"Neurosyphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Ocular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis may be associated with anterior uveitis, posterior uveitis, or panuveitis, which is often granulomatous. The most common form of posterior uveitis is multifocal chorioretinitis, but other manifestations include retinal necrosis and optic neuritis. Onset of uveitis can also occur in tertiary syphilis as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all stages of the disease, diagnosis of early syphilis is complicated by the fact that the organism has never been cultivated in vitro. The chancre of primary syphilis is best diagnosed by darkfield microscopy, if available (",
"    <a class=\"graphic graphic_picture graphicRef63806 \" href=\"mobipreview.htm?10/49/11037\">",
"     picture 9",
"    </a>",
"    ), while secondary syphilis is reliably diagnosed by serologic testing. A complete discussion of the serologic diagnosis of early syphilis appears elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cerebrospinal fluid analysis is not routinely recommended in patients with primary or secondary syphilis since there is no evidence that treatment failures after benzathine penicillin are more common in early syphilis in patients with an abnormal CSF analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]. The primary indications for lumbar puncture are clinical symptoms of meningitis or focal neurologic findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=see_link&amp;anchor=H15#H15\">",
"     \"Neurosyphilis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with latent syphilis should be evaluated clinically for evidence of tertiary disease (eg, aortitis and neurologic signs) and ocular disease (iritis and uveitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]. This includes careful auscultation of the heart for evidence of murmurs and visual acuity screening for any eye disease. If history or physical examination suggests tertiary disease, echocardiography or formal ophthalmologic examination may be warranted. If neurologic disease is suspected, the patient should also have a cerebrospinal fluid examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=see_link&amp;anchor=H15#H15\">",
"     \"Neurosyphilis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision of whether a lumbar puncture should be performed in HIV-infected patients with syphilis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with a genital ulcer, the differential diagnosis includes syphilis, genital herpes, and chancroid. Non-infectious causes include drug eruptions and Beh&ccedil;et&rsquo;s disease (",
"    <a class=\"graphic graphic_table graphicRef81735 \" href=\"mobipreview.htm?21/54/22381\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis based upon history and physical examination alone is often inaccurate. Nonetheless, some findings are more common in certain infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary syphilis classically presents with a painless, indurated, clean-based ulcer, called a chancre.",
"     </li>",
"     <li>",
"      Genital herpes is characterized by multiple, shallow, tender ulcers that may be vesicular; a history of recurrent disease may be elicited. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The classic genital presentation of chancroid is with a deep, undermined, purulent ulcer that may be associated with painful inguinal lymphadenitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10696?source=see_link\">",
"       \"Chancroid\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient acquired syphilis through oral sex, a syphilitic chancre may be noted in the oral cavity on the buccal mucosa, tongue, or lips [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/15\">",
"     15",
"    </a>",
"    ]. These syphilitic lesions can be misdiagnosed initially as herpetic or aphthous ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of penicillin for the treatment of all stages of syphilis has been established over approximately 50 years of its clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2,26,27\">",
"     2,26,27",
"    </a>",
"    ]. Thus, the recommendation for the use of penicillin is not based on any clinical trial or observational data, but a long history of clinical use.",
"   </p>",
"   <p>",
"    Antibiotic treatment of syphilis must be prolonged since T. pallidum divides slowly, averaging one doubling in vivo per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/28\">",
"     28",
"    </a>",
"    ]. For this reason, long-acting penicillin preparations are the preferred drugs for the treatment of all stages of syphilis.",
"   </p>",
"   <p>",
"    The following recommendations for the treatment of syphilis are consistent with the 2010 CDC guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Benzathine penicillin G",
"    </span>",
"    &nbsp;&mdash;&nbsp;T. pallidum apparently remains highly sensitive to penicillin, and no resistance has been reported to date despite several decades of use. Little sensitivity testing has been done because the organism must be isolated in rabbits. Although few comparative trials have been performed, a long experience using long-acting depot penicillin preparations has proven very successful in the treatment of early and late stages of syphilis. A single dose of benzathine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (2.4 million units IM) provides low but persistent serum levels of penicillin and is standard therapy for primary, secondary, or early latent syphilis (",
"    <a class=\"graphic graphic_table graphicRef50435 \" href=\"mobipreview.htm?26/1/26652\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2,29\">",
"     2,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Early syphilis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Late latent syphilis or latent syphilis of unknown duration requires three doses of 2.4 million units IM each at one-week intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Latent syphilis of unknown duration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Early syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only the long-acting benzathine preparation should be used for treatment of early syphilis since low and continuous levels of penicillin are necessary for the elimination of treponemes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/30\">",
"     30",
"    </a>",
"    ]. Long-acting benzathine penicillin should only be given via the intramuscular route; intravenous administration has been associated with cardiopulmonary arrest and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of Bicillin L-A (2.4 million units of benzathine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    ) leads to detectable serum concentrations that are prolonged for up to 30 days. Use of Bicillin C-R (equal concentrations of procaine and benzathine penicillin G), results in serum drug levels for only seven days. Inadvertent use of this shorter-acting preparation in a Los Angeles STD clinic led to a large-scale public health investigation and retesting and retreatment of a significant number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/31\">",
"     31",
"    </a>",
"    ]. The Bicillin C-R product is now labeled with a warning \"not for the treatment of syphilis\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Latent syphilis of unknown duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;If it is possible to document that the patient was infected with T. pallidum within the last year (eg, had a chancre or nonreactive syphilis serology within the past year), it is appropriate to treat with a single dose of benzathine penicillin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]. If not, the patient should be diagnosed with latent syphilis of unknown duration, or late latent syphilis, for which three doses of benzathine penicillin (2.4 million units IM) at weekly intervals are recommended (",
"    <a class=\"graphic graphic_table graphicRef50435 \" href=\"mobipreview.htm?26/1/26652\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2,29\">",
"     2,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Jarisch-Herxheimer reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;During penicillin therapy for syphilis, patients may develop the Jarisch-Herxheimer reaction, which is an acute febrile reaction frequently accompanied by headache and myalgias within the first 24 hours of treatment. This reaction is most common among patients with early syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]. Antipyretics can be used for symptomatic treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link&amp;anchor=H4310673#H4310673\">",
"     \"Syphilis in pregnancy\", section on 'Jarisch-Herxheimer reaction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Penicillin allergic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the treatment of early syphilis in penicillin allergic patients include tetracyclines, macrolides, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , although the data are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2,28,32\">",
"     2,28,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although macrolides have the advantage of single dose administration (2 gram oral dose), reports of macrolide resistance have been a source of concern (see",
"    <a class=\"local\" href=\"#H33\">",
"     'Macrolides'",
"    </a>",
"    below). For this reason, we prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    as our first line agent in the penicillin allergic nonpregnant patient.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    should be used only if adherence is a significant concern. When alternative agents to penicillin are used, close follow-up is essential.",
"   </p>",
"   <p>",
"    The effectiveness of alternatives to penicillin in the treatment of latent syphilis has not been well documented. The 2010 CDC STD guidelines recommend the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with early latent syphilis should respond to any of the options outlined above (tetracyclines, macrolides, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with late latent syphilis, or latent syphilis of unknown duration, should be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      as the preferred agent (100 mg twice daily) for 28 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In certain circumstances, such as pregnancy, penicillin is preferred even in the penicillin-allergic patient. In these circumstances, penicillin desensitization needs to be considered. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link&amp;anchor=H23#H23\">",
"     \"Syphilis in pregnancy\", section on 'Penicillin allergy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Tetracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early syphilis who are allergic to penicillin may be treated with 14 days of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg PO BID) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (500 mg PO four times daily), but these regimens are less well studied than penicillin. Doxycycline can also be considered if there are local epidemiologic concerns regarding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    resistance. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Macrolides'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Macrolides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of a single 2 gram oral dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    has been compared with 2.4 million units of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/50/12070?source=see_link\">",
"     penicillin G benzathine",
"    </a>",
"    intramuscularly in two randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial evaluated 328 patients with primary, secondary, or latent syphilis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/33\">",
"       33",
"      </a>",
"      ]. Fifty-two percent of the study population was HIV-seropositive. The primary outcome was serologic cure, defined as a decrease in the RPR titer by at least two dilutions at nine months of follow-up. For patients with primary and secondary syphilis, resolution of lesions within two weeks after treatment was also required. The study demonstrated equivalent cure rates between the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      and benzathine treatment groups (98 versus 95 percent), which did not vary by HIV status.",
"     </li>",
"     <li>",
"      A subsequent multicenter trial of 517 patients also showed equivalency of serologic cure rates for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      and benzathine penicillin at six months, although the overall cure rates were much lower (78 versus 79 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/34\">",
"       34",
"      </a>",
"      ]. HIV infection and pregnancy were exclusion criteria. Non-serious adverse events were more common in the azithromycin arm and were mainly gastrointestinal in nature.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these efficacy outcomes are encouraging, increasing reports of macrolide resistance have tempered enthusiasm for adopting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    for the treatment of syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. Studies demonstrate that the prevalence of azithromycin resistance varies widely depending on geography. For example, a substudy of the trial discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/34\">",
"     34",
"    </a>",
"    ] found no evidence of azithromycin resistance in Madagascar, which is the country where the largest number of subjects was enrolled; this observation may have accounted for the overall good treatment outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/40\">",
"     40",
"    </a>",
"    ]. However, in other areas, such as Shanghai, azithromycin resistance appears to be widespread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    resistance is due to an acquired 23S ribosomal RNA mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/37\">",
"     37",
"    </a>",
"    ]. This mutation has also been identified in Dublin, China, Seattle, and Baltimore [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/37\">",
"     37",
"    </a>",
"    ]. All but one of these identified cases has occurred in MSM. It is unclear if these strains represent a single clone spread within sexual networks in North America and Ireland or multiple strains that have emerged independently due to drug pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/41\">",
"     41",
"    </a>",
"    ]. In a study of 58 T. pallidum isolates that were screened for the 23S mutation, individuals who were exposed to macrolides in the previous year were approximately twice as likely to have a resistant strain of syphilis compared with subjects who had not taken macrolides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/42\">",
"     42",
"    </a>",
"    ]. The data from this small study in Seattle suggest that increases in the prevalence of macrolide-resistant T. pallidum strains are due to antibiotic pressure and not the spread of a clonal strain among small, defined sexual networks.",
"   </p>",
"   <p>",
"    Due to these concerns regarding the development of macrolide resistance, we recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    as the first line agent for the penicillin-allergic patient with early syphilis. Macrolides should only be used in geographic areas with a low prevalence of macrolide resistance or in patients with a history of medication non-adherence. Patients who are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    should be instructed that careful follow-up is essential and that they should return to the physician if symptoms persist. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Patient monitoring'",
"    </a>",
"    below.) The efficacy of azithromycin in pregnancy or in latent syphilis of unknown duration has not been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2,38\">",
"     2,38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Tetracyclines'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link&amp;anchor=H23#H23\">",
"     \"Syphilis in pregnancy\", section on 'Penicillin allergy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Ceftriaxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the rabbit model,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    has similar efficacy in the treatment of primary syphilis as penicillin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/43\">",
"     43",
"    </a>",
"    ]. Limited clinical data suggest that ceftriaxone may be effective for treatment of early latent and late latent syphilis; the optimal dose and duration have not been defined. Some specialists recommend 1 gram daily for 8 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients who are allergic to penicillin may also be allergic to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ; this agent should not be used in patients with a history of immediate hypersensitivity reactions to beta-lactams due to potential cross-reactivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should be reexamined clinically and serologically at six and 12 months after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2,44\">",
"     2,44",
"    </a>",
"    ]. A fourfold reduction in titer of the nontreponemal antibody test (eg, from 1:16 to 1:4) is considered evidence of an appropriate response.",
"   </p>",
"   <p>",
"    Unfortunately, some 15 percent of persons with early syphilis who receive recommended therapy do not achieve this fourfold decline at one year after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/45\">",
"     45",
"    </a>",
"    ]. It is not clear that this represents treatment failure since most such patients do not present with subsequent clinical findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18837?source=see_link\">",
"     \"Laboratory monitoring of patients undergoing treatment for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who do not have an appropriate decline in titer are managed by giving another course of benzathine penicillin (2.4 million units IM weekly for three weeks) and making sure all sexual contacts are also treated to decrease the risk of reinfection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]. The Centers for Disease Control and Prevention also recommends HIV testing and lumbar puncture in this situation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SCREENING AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no vaccine for syphilis. Patients should be educated that safer sex practices are vital for the prevention of infection. This includes barriers methods for vaginal, anal, and oral sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tracing and treating the sexual contacts of patients with infectious syphilis has been highly effective in limiting the further spread of the disease in communities. Contacts are treated with the same regimens as infected patients according to the following recommendations from the 2010 CDC guidelines on the treatment of STDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persons who were exposed within 90 days preceding the diagnosis of primary, secondary or early latent syphilis in a sex partner might be infected even if seronegative; therefore, such persons should be treated presumptively.",
"     </li>",
"     <li>",
"      Persons who were exposed &gt;90 days before the diagnosis of syphilis in a sex partner should be treated presumptively if follow-up is uncertain.",
"     </li>",
"     <li>",
"      Long-term sex partners of patients who have latent syphilis should be evaluated clinically and serologically for syphilis and treated on the basis of the evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients with HIV infection should be tested for syphilis, and",
"    <strong>",
"     all",
"    </strong>",
"    patients with early syphilis should be tested for HIV. In areas of high HIV seroprevalence, HIV-seronegative patients with primary syphilis should be rescreened for HIV in three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force (USPSTF) issued updated guidelines for syphilis screening in the summer of 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/46\">",
"     46",
"    </a>",
"    ]. A review of recent evidence increased the strength of support for the strategy of screening all pregnant women and people at higher risk of acquiring syphilis (MSM who engage in high risk behaviors, commercial sex workers, persons who exchange sex for drugs, and those in adult correctional facilities). The task force recommended against routine screening of asymptomatic persons who are not at increased risk of syphilis, since most positive tests in this setting represent false positive and can lead to unnecessary anxiety for patients, as well as increased costs and potential harm from inappropriate antibiotic use.",
"   </p>",
"   <p>",
"    Mass treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1.8 g PO once) was attempted in Vancouver, British Columbia in 2000 to address a dramatic increase in heterosexual syphilis cases associated with sex workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/47\">",
"     47",
"    </a>",
"    ]. The rates of syphilis fell significantly from a monthly mean of 10.2 before the treatment to 6.7 for the six months after mass treatment, but subsequently rose to higher than expected rates in 2001. Increasing evidence of resistance to azithromycin suggests this strategy is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37017/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/61/10195?source=see_link\">",
"       \"Patient information: Syphilis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syphilis is a chronic infection caused by the bacterium Treponema pallidum. Early syphilis is defined as the stages of syphilis (primary, secondary, and early latent syphilis) that typically occur within the first year after acquisition of the infection.",
"     </li>",
"     <li>",
"      Latent syphilis is characterized by asymptomatic infection with a normal physical examination in association with a positive serology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In primary syphilis, the classic lesion is a painless ulcer associated with mild to moderate regional lymphadenopathy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with secondary syphilis have marked systemic symptoms, such as malaise, fever, headache, and rash. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following antibiotics have activity against syphilis: penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    . For patients with early syphilis, we recommend penicillin as the drug of choice (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). We agree with the 2006 STD treatment guidelines issued by the CDC, as summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with primary or early latent syphilis, benzathine",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (formulated as Bicillin L-A at a dose of 2.4 million units) should be administered as a single dose.",
"     </li>",
"     <li>",
"      Patients with late latent syphilis or syphilis of unknown duration should be treated with three doses of benzathine penicillin (formulated only as Bicillin L-A at a dose of 2.4 million units) at weekly intervals. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-acting benzathine penicillin should only be given via the intramuscular route; intravenous administration has been associated with cardiopulmonary arrest and death. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who develop fever, headache, and myalgias consistent with Jarisch-Herxheimer reaction, antipyretics can be used for symptomatic relief. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Jarisch-Herxheimer reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe penicillin allergy, alternative agents for the treatment of syphilis include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      . We suggest doxycycline (100 mg twice daily for 14 days) as the preferred agent due to increasing reports of azithromycin resistance (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If there are concerns about medication nonadherence, we suggest a single dose of azithromycin (two grams) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Prior to azithromycin therapy, local public health officials should be consulted to determine local macrolide resistance patterns. When alternative agents to penicillin are used, close follow-up is essential.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Patient monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients should be reexamined clinically and serologically at six and 12 months after treatment. A fourfold reduction in titer of the nontreponemal antibody test is considered evidence of an appropriate response. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not have an appropriate decline in titer, we suggest another course of benzathine penicillin (2.4 million units IM for three weeks) for possible treatment failure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). All sexual contacts should be treated. The CDC also recommends HIV testing and diagnostic lumbar puncture for these patients. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Screening and prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with early syphilis should be tested for HIV. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Screening and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tracing and treating the sexual contacts of patients with infectious syphilis decreases transmission. Contacts are treated with the same regimens as infected patients. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Screening and prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/1\">",
"      Hook EW 3rd, Marra CM. Acquired syphilis in adults. N Engl J Med 1992; 326:1060.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/3\">",
"      Peterman TA, Kahn RH, Ciesielski CA, et al. Misclassification of the stages of syphilis: implications for surveillance. Sex Transm Dis 2005; 32:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/4\">",
"      Schachter J. Classification of latent syphilis: is it time to change the case definition? Sex Transm Dis 2005; 32:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/5\">",
"      Hart G. Syphilis tests in diagnostic and therapeutic decision making. Ann Intern Med 1986; 104:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis--United States, 1998. MMWR Morb Mortal Wkly Rep 1999; 48:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/7\">",
"      Mitka M. US effort to eliminate syphilis moving forward. JAMA 2000; 283:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases--United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention (CDC). 2009 Sexually transmitted Disease Surveillance &ndash; Syphilis. file://www.cdc.gov/std/stats09/syphilis.htm (Accessed on September 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/10\">",
"      Hook EW 3rd, Peeling RW. Syphilis control--a continuing challenge. N Engl J Med 2004; 351:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/11\">",
"      Chen ZQ, Zhang GC, Gong XD, et al. Syphilis in China: results of a national surveillance programme. Lancet 2007; 369:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/12\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/13\">",
"      Wong W, Chaw JK, Kent CK, Klausner JD. Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003. Sex Transm Dis 2005; 32:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Congenital syphilis--United States, 2002. MMWR Morb Mortal Wkly Rep 2004; 53:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Transmission of primary and secondary syphilis by oral sex--Chicago, Illinois, 1998-2002. MMWR Morb Mortal Wkly Rep 2004; 53:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/16\">",
"      French P. Syphilis. BMJ 2007; 334:143.",
"     </a>",
"    </li>",
"    <li>",
"     Musher D. Early syphilis. In: Sexually Transmitted Diseases, Holmes KK, Sparling PF, Mardh PA (Eds), McGraw-Hill, New York 1999. p.479.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/18\">",
"      Clark EG, Danbolt N. The Oslo study of the natural course of untreated syphilis: An epidemiologic investigation based on a re-study of the Boeck-Bruusgaard material. Med Clin North Am 1964; 48:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/19\">",
"      Pleimes M, Hartschuh W, Kutzner H, et al. Malignant syphilis with ocular involvement and organism-depleted lesions. Clin Infect Dis 2009; 48:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/20\">",
"      Chapel TA. The signs and symptoms of secondary syphilis. Sex Transm Dis 1980; 7:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/21\">",
"      Young MF, Sanowski RA, Manne RA. Syphilitic hepatitis. J Clin Gastroenterol 1992; 15:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/22\">",
"      Reginato AJ. Syphilitic arthritis and osteitis. Rheum Dis Clin North Am 1993; 19:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/23\">",
"      Hunte W, al-Ghraoui F, Cohen RJ. Secondary syphilis and the nephrotic syndrome. J Am Soc Nephrol 1993; 3:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/24\">",
"      Westeneng AC, Rothova A, de Boer JH, de Groot-Mijnes JD. Infectious uveitis in immunocompromised patients and the diagnostic value of polymerase chain reaction and Goldmann-Witmer coefficient in aqueous analysis. Am J Ophthalmol 2007; 144:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/25\">",
"      DiCarlo RP, Martin DH. The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis 1997; 25:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/26\">",
"      Mahoney JF, Arnold RC, Harris A. Penicillin Treatment of Early Syphilis-A Preliminary Report. Am J Public Health Nations Health 1943; 33:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/27\">",
"      Douglas JM Jr. Penicillin treatment of syphilis: clearing away the shadow on the land. JAMA 2009; 301:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/28\">",
"      MAGNUSON HJ, THOMAS EW, OLANSKY S, et al. Inoculation syphilis in human volunteers. Medicine (Baltimore) 1956; 35:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/29\">",
"      Drugs for sexually transmitted infections. Treat Guidel Med Lett 2004; 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     The Pink Sheet\" F-D-C Reports, Chevy Chase, MD, December 6, 2004, p. 17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Inadvertent use of Bicillin C-R to treat syphilis infection--Los Angeles, California, 1999-2004. MMWR Morb Mortal Wkly Rep 2005; 54:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/32\">",
"      Gruber F, Kastelan M, Cabrijan L, et al. Treatment of early syphilis with azithromycin. J Chemother 2000; 12:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/33\">",
"      Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005; 353:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/34\">",
"      Hook EW 3rd, Behets F, Van Damme K, et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis 2010; 201:1729.",
"     </a>",
"    </li>",
"    <li>",
"     Bai ZG, Wang B, Yang K, Tian JH, Ma B, Liu Y, Jiang L, Gai QY, He X, LiY. Azithromycin versus penicillin G benzathine for early syphilis. Cochrane Database of Systematic Reviews 2012, Issue 6. Art No.: CD007270.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/36\">",
"      Centers for Disease Control and Prevention (CDC). Azithromycin treatment failures in syphilis infections--San Francisco, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/37\">",
"      Lukehart SA, Godornes C, Molini BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004; 351:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/38\">",
"      Ballard RC, Berman SM, Fenton KA. Azithromycin versus penicillin for early syphilis. N Engl J Med 2006; 354:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/39\">",
"      Martin IE, Gu W, Yang Y, Tsang RS. Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China. Clin Infect Dis 2009; 49:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/40\">",
"      Van Damme K, Behets F, Ravelomanana N, et al. Evaluation of azithromycin resistance in Treponema pallidum specimens from Madagascar. Sex Transm Dis 2009; 36:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/41\">",
"      Holmes KK. Azithromycin versus penicillin G benzathine for early syphilis. N Engl J Med 2005; 353:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/42\">",
"      Marra CM, Colina AP, Godornes C, et al. Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. J Infect Dis 2006; 194:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/43\">",
"      Johnson RC, Bey RF, Wolgamot SJ. Comparison of the activities of ceftriaxone and penicillin G against experimentally induced syphilis in rabbits. Antimicrob Agents Chemother 1982; 21:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/44\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of syphilis among men who have sex with men--Southern California, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/45\">",
"      Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997; 337:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/46\">",
"      Calonge N, U.S. Preventive Services Task Force. Screening for syphilis infection: recommendation statement. Ann Fam Med 2004; 2:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37017/abstract/47\">",
"      Rekart ML, Patrick DM, Chakraborty B, et al. Targeted mass treatment for syphilis with oral azithromycin. Lancet 2003; 361:313.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7594 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-90821EDB07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37017=[""].join("\n");
var outline_f36_9_37017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Early syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Latent syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Men who have sex with men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Women and minority groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Incubating syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Primary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rash",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Systemic symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Alopecia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Gastrointestinal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Musculoskeletal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Renal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Neurologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Ocular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Benzathine penicillin G",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Early syphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Latent syphilis of unknown duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Jarisch-Herxheimer reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Penicillin allergic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Macrolides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Ceftriaxone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SCREENING AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Patient monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Screening and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7594\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7594|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/12/30925\" title=\"figure 1\">",
"      Primary secondary syphilis US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7594|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/16/17664\" title=\"picture 1\">",
"      Penile chancre in syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/22/12642\" title=\"picture 2\">",
"      Papular secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/13/15583\" title=\"picture 3\">",
"      Trunk rash secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/3/9279\" title=\"picture 4\">",
"      Rash in secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/15/43251\" title=\"picture 5\">",
"      Mucous patch secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/12/26818\" title=\"picture 6\">",
"      Condyloma lata syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/45/41695\" title=\"picture 7\">",
"      Lymphadenopathy in syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/57/33683\" title=\"picture 8\">",
"      Alopecia in secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/49/11037\" title=\"picture 9\">",
"      Penile ulcer dark field answer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7594|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/54/22381\" title=\"table 1\">",
"      GUD clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/1/26652\" title=\"table 2\">",
"      Rx syphilis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18837?source=related_link\">",
"      Laboratory monitoring of patients undergoing treatment for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26312?source=related_link\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12150?source=related_link\">",
"      Pathophysiology, transmission, and natural history of syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/61/10195?source=related_link\">",
"      Patient information: Syphilis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=related_link\">",
"      Syphilis in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_9_37018="Major side effects of class I antiarrhythmic drugs";
var content_f36_9_37018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Major side effects of class I antiarrhythmic drugs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37018/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37018/contributors\">",
"     Elsa-Grace Giardina, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37018/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/9/37018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/9/37018/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/9/37018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16747152\">",
"    <span class=\"h1\">",
"     DISOPYRAMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effect profile of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    has been well established. Anticholinergic symptoms are most common, but cardiac toxicity is of greatest concern. In particular, the negative inotropic activity and proarrhythmic potential of disopyramide limits its use in settings in which it might otherwise be effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747481\">",
"    <span class=\"h2\">",
"     Anticholinergic side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    is associated with a number of anticholinergic symptoms including dry mouth (32 percent), urinary hesitancy (14 percent), and constipation (11 percent). As a result, disopyramide should not be used in patients with underlying conditions that may be exacerbated by decreased cholinergic activity including glaucoma, myasthenia gravis, and urinary retention.",
"   </p>",
"   <p>",
"    The anticholinergic effects can be diminished by the coadministration of drugs that increase cholinergic activity such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25476?source=see_link\">",
"     bethanechol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/1\">",
"     1",
"    </a>",
"    ]. These agents selectively reduce anticholinergic symptoms without affecting the electrophysiologic or antiarrhythmic properties of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     Disopyramide",
"    </a>",
"    concentration and its metabolite, mono-N-dealkyldisopyramide, concentration should be monitored in patients whose renal function is decreased to prevent anticholinergic side effects associated with disopyramide. When serum mono-N-dealkyldisopyramide concentration is over approximately 1",
"    <span class=\"nowrap\">",
"     microg/mL,",
"    </span>",
"    the dose should be decreased or discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747488\">",
"    <span class=\"h2\">",
"     Cardiac toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     Disopyramide",
"    </a>",
"    has substantial negative inotropic activity in humans, resulting in reductions in cardiac contractility and cardiac output, and a reflex increase in systemic vascular resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/4\">",
"     4",
"    </a>",
"    ]. The degree to which this can occur has been clearly documented in studies in dogs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. When given intravenously, disopyramide causes a significant decline in cardiac contractility at doses as low as 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight (similar to that administered intravenously in humans). At higher doses (5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    the decrease in contractile force is 50 to 100 percent greater than that induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These changes can lead to overt heart failure (HF). HF usually occurs within the first three weeks of therapy; however, it can be seen as soon as 48 hours after the initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    or as long as several months later. This complication is most likely to occur with preexisting heart failure, affecting 55 percent of such patients versus only 5 percent without a prior history of heart disease. Intravenous drug administration and concurrent renal failure are other risk factors for a significant decline in myocardial function. In one study, for example, intravenous disopyramide (2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    lowered the cardiac index by 10 to 25 percent in patients with underlying heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/7\">",
"     7",
"    </a>",
"    ]. In rare cases, cardiogenic shock has been induced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decline in contractility generally resolves rapidly after discontinuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    . There may, however, be an acute requirement for therapy with diuretics, inotropic agents, or afterload reducing drugs. Prior treatment with these agents in patients at high risk also may be beneficial. Other suggestions to enhance the safety of disopyramide in patients with underlying myocardial dysfunction include avoidance of loading doses or intravenous administration, and careful dose titration. Consideration should also be given to alternative antiarrhythmic drugs that do not have important negative inotropic activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747495\">",
"    <span class=\"h3\">",
"     Electrocardiographic and proarrhythmic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant widening of the QRS interval occurs in a minority of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    . This is most likely to occur at high circulating drug levels, but may be seen with values in the therapeutic range. Therapy should be discontinued until the plasma disopyramide concentration is determined.",
"   </p>",
"   <p>",
"    Like other class IA antiarrhythmic drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    can prolong the QT interval, possibly leading to increased ventricular ectopy, torsades de pointes (a form of polymorphic ventricular tachycardia), or syncope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/9\">",
"     9",
"    </a>",
"    ]. Concurrent use of other class I or class III agents (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ) can produce an additive increase in both the QRS and QT intervals. A similar effect can be induced by the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , drugs that inhibit the metabolism of disopyramide by inhibiting CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    may be safer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/13\">",
"     13",
"    </a>",
"    ], but potentially fatal ventricular arrhythmias can be induced when used in combination with disopyramide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     Disopyramide",
"    </a>",
"    should be discontinued if the QT interval increases by more than 25 percent or ventricular ectopy is exacerbated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proarrhythmic potential for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    (6 percent) is less than that for the other class IA drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    (15 percent) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    (9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/15\">",
"     15",
"    </a>",
"    ]. With each of these drugs, the likelihood of proarrhythmia is increased by hypokalemia, hypomagnesemia, and bradyarrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    (an initial 2 g bolus, with repeated doses as needed) has been useful in patients with QT prolongation and torsades de pointes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Magnesium may act by suppressing afterdepolarizations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747502\">",
"    <span class=\"h3\">",
"     Increased ventricular response during atrial fibrillation or flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other class IA antiarrhythmic drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    can significantly increase the ventricular rate in patients with uncontrolled atrial fibrillation or flutter. Two factors contribute to this response: disopyramide slows the fibrillation or flutter rate, thereby making it more likely that a given impulse will pass through the AV node; and the direct anticholinergic effect of disopyramide enhances AV nodal conduction. Thus, the AV node must be slowed and the ventricular rate controlled (with &szlig;-blockers, calcium channel blockers, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) before therapy with disopyramide is begun. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747509\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is an occasional complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. How this occurs is incompletely understood. Animal studies have shown that disopyramide enhances insulin release, an effect that may be mediated by inhibition of potassium channels in the insulin-secreting cells. Although the applicability of these observations to humans is uncertain, increased plasma insulin levels have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies from recordings of pancreatic Beta cell K(ATP) channels indicate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    -induced inhibition of K(ATP) channels is sufficient to cause Beta-cell membrane depolarization and stimulate insulin secretion. Disopyramide therapy is not recommended for patients treated with K(ATP) channel inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     glimepiride",
"    </a>",
"    treatment since the synergistic effect stimulates insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of development hypoglycemia is increased with concurrent ingestion of drugs that inhibit CYP3A4, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747524\">",
"    <span class=\"h2\">",
"     Safety of disopyramide in obstructive hypertrophic cardiomyopathy (HCM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     Disopyramide",
"    </a>",
"    does not appear to induce proarrhythmia in HCM and should be considered before surgical myectomy or alternate strategies. The long-term efficacy and safety of disopyramide for patients with HCM were evaluated in 118 obstructive HCM patients treated with disopyramide at four centers. Two-thirds of obstructed HCM patients treated with disopyramide could be managed medically with amelioration of symptoms and about 50 percent reduction in subaortic gradient over",
"    <span class=\"nowrap\">",
"     &gt;/=3",
"    </span>",
"    years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747160\">",
"    <span class=\"h1\">",
"     PROCAINAMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     Procainamide",
"    </a>",
"    is an effective antiarrhythmic drug. However, its use is frequently limited by side effects, particularly a lupus-like syndrome and, although infrequent, potentially severe bone marrow toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748111\">",
"    <span class=\"h2\">",
"     Systemic signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nonspecific systemic symptoms can be induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    . These include gastrointestinal disturbances (anorexia, nausea, vomiting), central nervous dysfunction (headache, insomnia, dizziness, psychosis, hallucination, depression), fever, rash (morbilliform urticaria), myalgias, digital vasculitis, and Raynaud's phenomenon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748118\">",
"    <span class=\"h2\">",
"     Lupus-like syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    is associated with a positive antinuclear antibody titer in almost all patients, particularly slow acetylators. However, symptoms similar to those seen in lupus (eg, arthritis, arthralgias, and pleuritis) develop in only 15 to 20 percent of patients; why this occurs is not known. The clinical manifestations typically remit when therapy is discontinued or changed to N-acetylprocainamide, the major active metabolite of procainamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/25\">",
"     25",
"    </a>",
"    ]. The inability of N-acetylprocainamide to induce the lupus-like syndrome suggests an important pathogenetic role for the aromatic amino group on procainamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748125\">",
"    <span class=\"h2\">",
"     Blood dyscrasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancytopenia or agranulocytosis is a rare but potentially life-threatening complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    therapy that may be mediated by allergic, hypersensitivity, or immunologic mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. These complications, which in one report occurred with an estimated incidence of 0.22 percent, usually develop within three months after the initiation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Drug withdrawal is indicated in all cases; however, there is a variable degree of recovery of the white blood cell count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748132\">",
"    <span class=\"h2\">",
"     Cardiac toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some of the cardiac side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    can be seen at therapeutic levels, a variety of more serious and potentially lethal effects are more common at toxic plasma levels (above 30",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    for procainamide plus its major metabolite N-acetylprocainamide versus a therapeutic range of 4 to 12",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    for procainamide alone). Among the changes that can occur are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conduction delay, manifested by progressive PR prolongation or widening of the QRS interval.",
"     </li>",
"     <li>",
"      Prolonged refractoriness, leading to prolongation of the QT interval in proportion to the plasma",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      concentration.",
"     </li>",
"     <li>",
"      Arrhythmias, such as ventricular premature contractions and ventricular tachycardia.",
"     </li>",
"     <li>",
"      Severe depression of left ventricular function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748139\">",
"    <span class=\"h3\">",
"     Effects on ECG intervals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram can be used to monitor both the therapeutic and toxic effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    on the heart. Procainamide has a variety of effects on cardiac conduction at both therapeutic and toxic levels. These effects are due to both a direct influence on electrophysiologic properties and the indirect impact of autonomic modulation (vagolytic properties).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748146\">",
"    <span class=\"h4\">",
"     Sinus rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic plasma levels have little influence on the sinus rate, but may slightly increase the sinus rate due to a vagolytic effect. In contrast, the sinus rate may be depressed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748153\">",
"    <span class=\"h4\">",
"     PR interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     Procainamide",
"    </a>",
"    has little effect on the PR interval if atrioventricular (AV) conduction is normal. If, however, there is preexisting slowing of AV conduction, then procainamide can depress conduction further, leading to higher degrees of AV block even at therapeutic drug levels. The risk of heart block in this setting is heightened since procainamide also reduces ventricular automaticity. Thus, there might be no ventricular escape rhythm if complete heart block develops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748160\">",
"    <span class=\"h4\">",
"     QRS duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    concentrations widen the QRS complex due to slowing of conduction in the Purkinje system and ventricular muscle. The drug should be discontinued if the QRS duration increases by more than 35 to 50 percent to avoid serious toxicity. Toxic plasma levels can cause intraventricular conduction disturbances and reentry, possibly resulting in ventricular arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748167\">",
"    <span class=\"h4\">",
"     QT interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     Procainamide",
"    </a>",
"    prolongs the QT interval, usually in proportion to the plasma procainamide concentration. Marked prolongation occurring in conjunction with hypokalemia can cause early afterdepolarizations and triggered activity that can lead to ventricular tachycardia.",
"   </p>",
"   <p>",
"    Other medications that prolong the QT interval, such as fluoroquinolones and certain antihistamines (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"mobipreview.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ), should be avoided in patients with known prolongation of the QT interval, and patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748174\">",
"    <span class=\"h3\">",
"     Proarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proarrhythmic effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    can occur at normal plasma drug concentrations. The most common arrhythmia is torsades de pointes (a form of polymorphic ventricular tachycardia), which can also be induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and by the Class IC antiarrhythmic drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    . It has been estimated that proarrhythmia occurs in 3 to 12 percent of patients taking usual doses of procainamide. This incidence is lower than that seen with quinidine or the other agents, perhaps because procainamide produces a less prominent prolongation of the QT interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748181\">",
"    <span class=\"h3\">",
"     Increased ventricular response during atrial fibrillation or flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     Procainamide",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    , can significantly increase the ventricular rate in patients with uncontrolled atrial fibrillation or flutter. Two factors contribute to this response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By slowing the atrial rate of atrial fibrillation or atrial flutter,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      increases the likelihood that a given impulse will pass through the atrioventricular (AV) node, thereby potentially increasing the ventricular rate.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       Procainamide",
"      </a>",
"      has a direct vagolytic action on the AV node, thereby increasing conduction through the AV node.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, when administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    for chemical cardioversion of atrial fibrillation, conduction through the AV node must be slowed and the ventricular response controlled (using &szlig;-blockers, calcium channel blockers, or digitalis) before therapy with procainamide is initiated in these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748188\">",
"    <span class=\"h3\">",
"     Left ventricular dysfunction and vascular resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide studies have shown that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    decreases left ventricular performance slightly at usual doses, but significant myocardial depression can occur at toxic concentrations or after large intravenous doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a similar dose-dependence to the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    on blood pressure and vascular resistance. This relationship has been best studies in experimental animals as neither of these parameters changes significantly at usual therapeutic doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, rapid, high-dose intravenous procainamide administration can lead to hypotension, reductions in systemic and pulmonary vascular resistance, and a fall in cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A historical cohort study of patients with hemodynamically stable sustained ventricular tachycardia (VT) was treated with IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    to compare their effectiveness for the termination of VT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/37\">",
"     37",
"    </a>",
"    ]. Major adverse effects were tabulated, and blood pressure responses to medication infusions were compared. As used in practice, both agents were relatively ineffective for terminating VT and were associated with clinically important proportions of patients with decreased blood pressure. Hypotension led to cessation of medicine infusion or immediate direct current cardioversion in",
"    <span class=\"nowrap\">",
"     4/66",
"    </span>",
"    (6 percent) who received amiodarone and",
"    <span class=\"nowrap\">",
"     6/31",
"    </span>",
"    (19 percent) patients who received procainamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748195\">",
"    <span class=\"h2\">",
"     Pyrexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever can be a manifestation of an allergic response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    and may lead to unnecessary testing, hospitalization, and treatment if unrecognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16748202\">",
"    <span class=\"h2\">",
"     Psychosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosis is a rare complication of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , and the exact mechanism for this adverse event is not fully understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/39\">",
"     39",
"    </a>",
"    ]. Seven cases implicating procainamide as the cause of acute psychosis responded to discontinuation of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747168\">",
"    <span class=\"h1\">",
"     QUINIDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     Quinidine",
"    </a>",
"    is a class Ia antiarrhythmic agent (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"mobipreview.htm?2/52/2892\">",
"     table 3",
"    </a>",
"    ) that can be used to treat both atrial and ventricular arrhythmias. While no longer as commonly used as some other antiarrhythmic agents, primarily due to concern about side effects (",
"    <a class=\"graphic graphic_table graphicRef65568 \" href=\"mobipreview.htm?32/56/33676\">",
"     table 4",
"    </a>",
"    ), particularly proarrhythmia and sudden death, quinidine may still be used in a subset of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749142\">",
"    <span class=\"h2\">",
"     Cardiovascular toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of potential cardiac toxicities related to the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , including proarrhythmia, conduction disturbances, hypotension, and congestive heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749149\">",
"    <span class=\"h3\">",
"     Proarrhythmia and ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias, including isolated ventricular premature beats, couplets, bigeminy, and ventricular tachycardia, can be induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/41\">",
"     41",
"    </a>",
"    ]. As an example, \"quinidine syncope\", which is probably due to self-terminating torsades de pointes (a form of polymorphic ventricular tachycardia), has been reported to occur in 1.5 percent of patients per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/42\">",
"     42",
"    </a>",
"    ]. This complication is unrelated to the plasma quinidine level or the duration of therapy and it often occurs when plasma concentrations are normal or below the therapeutic range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Thus, the induction of arrhythmias appears to reflect the proarrhythmic effect of quinidine, rather than true toxicity. Furthermore, there is suggestive evidence that these arrhythmias may be fatal, leading to lower survival rates in patients treated with quinidine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/24/12682?source=see_link&amp;anchor=H5#H5\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Class IA antiarrhythmic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     Quinidine",
"    </a>",
"    syncope and torsades de pointes are frequently associated with significant QT prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. Torsades de pointes may be precipitated or aggravated by a number of conditions including hypokalemia, hypomagnesemia, and bradycardia, and concurrent therapy with digitalis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/42,44,45\">",
"     42,44,45",
"    </a>",
"    ]. Other antiarrhythmic drugs that prolong the QT interval (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ) should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749156\">",
"    <span class=\"h4\">",
"     Treatment of torsades de pointes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of torsades de pointes requires immediate discontinuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and of any other drug that prolongs the QT interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/46\">",
"     46",
"    </a>",
"    ]. Torsade appears to be induced by triggered activity resulting from early afterdepolarizations associated with QT prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. One goal of therapy is to increase the heart rate, thereby shortening the delay in repolarization, either by pacing the atrium or ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/49\">",
"     49",
"    </a>",
"    ] or by the administration of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/50\">",
"     50",
"    </a>",
"    ]. Torsade can also be suppressed by intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    (2 g over one to two minutes, followed by a maintenance infusion rate of 3 to 20",
"    <span class=\"nowrap\">",
"     mg/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/18\">",
"     18",
"    </a>",
"    ]. In a review comparing the efficacy of different therapeutic modalities, torsade was terminated in 19 of 19 patients treated with DC countershock, 9 of 9 who underwent ventricular pacing at rates of 100 to 120",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    5 of 6 treated with isoproterenol, and only 7 of 14 receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749163\">",
"    <span class=\"h4\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkalinization with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/21/8530?source=see_link\">",
"     sodium lactate",
"    </a>",
"    (lactate is rapidly metabolized to bicarbonate) may diminish the cardiac toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/40,51\">",
"     40,51",
"    </a>",
"    ]. At the level of the sodium channel, which is blocked by quinidine in part via a charge effect of this cationic drug, alkalosis will enhance recovery of the sodium channel by at least two mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It will hyperpolarize the cell by decreasing the extracellular potassium concentration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25891?source=see_link\">",
"       \"Potassium balance in acid-base disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It will drive the reaction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Qud+ &nbsp; + &nbsp; OH- &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;QudOH",
"   </p>",
"   <p>",
"    to the right, thereby decreasing the availability of the active charged form of the drug. It has also been hypothesized that administration of a sodium containing solution directly reverses the sodium channel blockade.",
"   </p>",
"   <p>",
"    An intravenous infusion of potassium, even in the presence of a normal serum potassium may also be helpful. As an example, one study of 12 normal subjects and 8 patients with congestive heart failure treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    reported that administration of intravenous potassium (0.5",
"    <span class=\"nowrap\">",
"     mEq/kg",
"    </span>",
"    to a maximum of 40 mEq) reversed QT prolongation and QT morphologic changes (u waves and bifid T waves) and decreased QT dispersion, while increasing the serum potassium by only 0.7",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/53\">",
"     53",
"    </a>",
"    ]. It is uncertain, however, if this therapy is effective for preventing or reversing torsades de pointes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749170\">",
"    <span class=\"h4\">",
"     Gender differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are more susceptible to QT interval prolongation and torsades de pointes after the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and other drugs that delay cardiac repolarization. This effect appears to be independent of serum drug levels. A study of 45 healthy volunteers (21 women) compared serum quinidine levels and changes in QRS and QT intervals between men and women. The following findings were reported: [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no differences in the plasma concentrations or pharmacokinetic variables between men and women.",
"     </li>",
"     <li>",
"      Women demonstrated a significantly greater increase in QTc compared to men (33 versus 24 ms increase).",
"     </li>",
"     <li>",
"      Women also had a significantly greater increase in QRS duration, which explained much of the QT increase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the disparity in prolongation of cardiac repolarization is due to a pharmacodynamic difference, and appears to involve gender-specific effects on both depolarization and repolarization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749177\">",
"    <span class=\"h3\">",
"     Conduction disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac toxicity associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    may be initially manifested by slowed sinus or atrioventricular (AV) nodal conduction, causing sinus node conduction abnormalities or AV block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Higher plasma concentrations may lead to marked QRS widening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749184\">",
"    <span class=\"h3\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     Quinidine",
"    </a>",
"    lowers the blood pressure and can induce hypotension, particularly if large doses are administered rapidly and intravenously. The fall in blood pressure is due both to direct vasodilation and to inhibition of alpha-adrenergic mediated vasoconstriction in arteries and veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/58\">",
"     58",
"    </a>",
"    ]. The hemodynamic effects of oral quinidine are similar but less pronounced.",
"   </p>",
"   <p>",
"    Hypotension, requiring either slowing or cessation of intravenous therapy, occurs in approximately 25 percent of patients. Some reports have demonstrated a good response to 500 mL of isotonic saline, a regimen that can be tolerated even in patients with significant heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749191\">",
"    <span class=\"h3\">",
"     Increased ventricular response during atrial fibrillation or flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     Quinidine",
"    </a>",
"    can significantly increase the ventricular rate in patients with uncontrolled atrial fibrillation or flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/40\">",
"     40",
"    </a>",
"    ]. Two factors contribute to this response. By slowing the atrial fibrillation or atrial flutter rate, quinidine increases the likelihood that a given impulse will pass through the atrioventricular (AV) node. This tendency is enhanced by the direct vagolytic action of quinidine. Thus, conduction through the AV node must be slowed and the ventricular response controlled (using &szlig;-blockers, calcium channel blockers, or digitalis) before therapy with quinidine is initiated in these disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749198\">",
"    <span class=\"h3\">",
"     Myocardial toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies, including those in denervated dogs and human heart transplant recipients, have failed to demonstrate a marked cardio-depressant effect of therapeutic levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/59\">",
"     59",
"    </a>",
"    ]. However, this possibility should be considered when a patient with known left ventricular dysfunction has new or worsening symptoms of heart failure while treated with quinidine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749205\">",
"    <span class=\"h2\">",
"     Gastrointestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent adverse effects with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    are gastrointestinal, including nausea, diarrhea, and abdominal bloating and discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/40\">",
"     40",
"    </a>",
"    ]. These symptoms may be less severe with the gluconate preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749212\">",
"    <span class=\"h2\">",
"     Central nervous system toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system toxicity is associated with high-dose therapy and subsequent high plasma",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    levels. The constellation of symptoms that may be seen is called cinchonism and includes tinnitus, hearing loss, confusion, delirium, disturbances in vision, and psychosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749219\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    has been associated with hypoglycemia in patients treated for severe malaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13338?source=see_link\">",
"     \"Treatment of severe falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749226\">",
"    <span class=\"h2\">",
"     Immune-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of immune-mediated reactions may be induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    therapy, such as rash, fever, hemolytic anemia, thrombocytopenia, leukopenia, hepatotoxicity, and anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/40\">",
"     40",
"    </a>",
"    ]. Thrombocytopenia, for example, results from antibodies to quinidine-platelet complexes, which cause platelets to agglutinate and lyse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/62\">",
"     62",
"    </a>",
"    ]. A lupus-like syndrome, similar to that induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , is a rare problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749233\">",
"    <span class=\"h2\">",
"     Interaction with grapefruit juice",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     Quinidine",
"    </a>",
"    is metabolized by the cytochrome P450 system and it is a substrate of the CYP3A4 enzyme. Since CYP3A4 activity can be affected by grapefruit juice, concerns have been raised about the potential toxicity of quinidine and other cardiac drugs after grapefruit juice ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/64\">",
"     64",
"    </a>",
"    ]. The only significant difference in pharmacokinetic parameters of quinidine when administered with grapefruit juice is a delay in the time to maximum concentration (tmax) by approximately two hours. Administration with grapefruit juice also results in a 33 percent decrease in the area under the concentration-time curve (AUC) of 3-hydroxyquinidine, but does not increase the AUC of quinidine or change the ratio of AUC of 3-hydroxyquinidine to the AUC of quinidine.",
"   </p>",
"   <p>",
"    Pharmacodynamic parameters, including changes in the rate-corrected QT (QTc) interval, closely parallel the pharmacokinetic data, in that administration with grapefruit juice leads to delayed maximal effect on QTc and reduction in maximal effect. Administration with grapefruit juice therefore delays the absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and inhibits the metabolism of quinidine to 3-hydroxyquinidine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16749240\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of 44 randomized controlled trials with a total of 11,322 subjects evaluated the efficacy and adverse events of class IA antiarrhythmic drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    ), Class IC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ) and Class III (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ) in atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/65\">",
"     65",
"    </a>",
"    ]. Quinidine significantly reduced recurrences of atrial fibrillation (p&lt;0.001) and was associated with more withdrawals than other class I drugs (p&lt;0.001), but not more proarrhythmia than others. Mortality associated with quinidine alone trended toward significance (p&lt;0.07), and Class IA drugs when pooled (quinidine, disopyramide) were associated with an increased mortality compared to controls (p&lt;0.04). No other antiarrhythmic agent showed a significant effect on mortality compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747176\">",
"    <span class=\"h1\">",
"     LIDOCAINE (INTRAVENOUS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    , administered intravenously in the treatment of ventricular arrhythmias, is generally well tolerated. The major side effects primarily involve the central nervous system, the cardiovascular system, and the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16750194\">",
"    <span class=\"h2\">",
"     Neurologic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse effect of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is central nervous system (CNS) toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. The symptoms are usually mild, dose-dependent, and always resolve with a decrease in the infusion rate or discontinuation of the drug. These side effects may be particularly frequent in older adults or in those with heart failure, settings in which CNS levels are increased due to a reduced volume of distribution, and in patients with significant liver impairment in whom the metabolism of lidocaine is reduced.",
"   </p>",
"   <p>",
"    Tremor is a useful bedside sign of toxicity. Other neurologic side effects include insomnia or drowsiness, lightheadedness, dysarthria and slurred speech, ataxia, depression, agitation, change in sensorium, a change in personality, nystagmus, hallucinations, memory impairment, and emotional lability.",
"   </p>",
"   <p>",
"    High plasma concentrations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    can also provoke seizures that are usually generalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/70\">",
"     70",
"    </a>",
"    ]. This can also occur at lower drug concentrations if lidocaine is given to patients receiving oral tocainide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    , which are congeners of lidocaine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16750201\">",
"    <span class=\"h2\">",
"     Cardiovascular toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac side effects are an infrequent complication of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    therapy which is generally well tolerated even by patients with significant underlying heart disease. The primary cardiovascular side effects include sinus slowing, asystole, hypotension, and shock. These problems are most often associated with overdosing or with the overly rapid administration of lidocaine. The elderly and those with significant preexisting heart disease are at greatest risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little is known about proarrhythmia due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . Its specificity of action and relatively short half-life probably provide a great degree of safety. The potential for lidocaine to exacerbate or provoke arrhythmia has not been systematically evaluated. However, if lidocaine does have any proarrhythmic effects, its use over many years in the unstable phase of myocardial infarction has provided ample opportunity for any significant risk to have been identified.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    produces a dose-dependent increase in the defibrillation threshold in animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/73\">",
"     73",
"    </a>",
"    ]. Although there are no clinical data available, lidocaine should be used cautiously in patients with an implantable cardioverter-defibrillator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16750208\">",
"    <span class=\"h2\">",
"     Gastrointestinal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal side effects, including nausea, vomiting and anorexia, can occur with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    and are not always dose-dependent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747192\">",
"    <span class=\"h1\">",
"     MEXILETINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    are generally dose- and concentration-dependent. The most common adverse effects are related to the gastrointestinal and central nervous systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Common digestive complaints include nausea, vomiting, or heartburn. These symptoms are reversible and can be reduced by food or antacid administration. The most frequent central nervous system complaints are dizziness, lightheadedness, tremor, nervousness, difficulty with coordination, change in sleep habits, paresthesias, and numbness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. More serious noncardiac side effects are rare. Thrombocytopenia has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/76\">",
"     76",
"    </a>",
"    ] as has a positive antinuclear-antibody titer that regresses with discontinuation of therapy. Hepatitis is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16750517\">",
"    <span class=\"h2\">",
"     Cardiac complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two potential cardiac complications associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    : proarrhythmia; and impaired hemodynamics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16750524\">",
"    <span class=\"h3\">",
"     Proarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with many other antiarrhythmic agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    has a proarrhythmic effect. This is of greatest concern in patients with life-threatening arrhythmias such as sustained ventricular tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Exacerbation of arrhythmia after mexiletine occurs in 10 to 15 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     Mexiletine",
"    </a>",
"    also has a depressant effect on sinus node function. This can result in sinus bradycardia or prolonged sinus node recovery time in patients with preexisting sinus node dysfunction or following administration of very high doses of mexiletine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/15,77\">",
"     15,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16750531\">",
"    <span class=\"h3\">",
"     Hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     Mexiletine",
"    </a>",
"    is usually well tolerated hemodynamically, lacking the potent negative inotropic effects seen with other drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , and &szlig;-blockers. Nevertheless, in patients with severe congestive heart failure, mexiletine should be used with caution because it can aggravate the heart failure or cause hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Cardiodepressant effects may be more evident in patients with severe left ventricular dysfunction. Dosing that results in a high (but still therapeutic) plasma level is more likely to cause hemodynamic deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/82\">",
"     82",
"    </a>",
"    ]. Furthermore, hepatic metabolism may be impaired in heart failure, resulting in prolongation of the elimination half-life of mexiletine to 25 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16750538\">",
"    <span class=\"h2\">",
"     Dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Truncal erythema, marked facial edema, with erythema and pustules extending to the extremities and face may be related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    . In a case report, a patient treated with mexiletine developed erythema and edema which regressed when mexiletine was discontinued over two to three weeks; patch tests with 10 percent and 20 percent mexiletine hydrochloride in petrolatum showed a positive reaction. Thus, infiltrated erythema and facial edema could be signs of acute exanthematous pustular drug eruption induced by mexiletine hydrochloride [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16750545\">",
"    <span class=\"h2\">",
"     Mexiletine-induced hypersensitivity syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     Mexiletine",
"    </a>",
"    -induced hypersensitivity syndrome occurs most frequently in Japanese males and is manifested by fever, rash, peripheral blood eosinophilia, and elevation of liver transaminase enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. The clinical response develops three weeks to three months after starting mexiletine. Although the mechanism for the immunogenicity is not clear, a role of reactive drug metabolites in initiating an immune response via hapten formation has been suggested. The involvement of viral infection has been explored suggesting a relationship between human herpes virus 6 and the development of systemic immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16750552\">",
"    <span class=\"h2\">",
"     Overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few cases of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    overdose have been reported in the literature and most of the available case reports have noted significant hemodynamic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrocardiographic abnormalities. However, overdose can also be associated with generalized motor seizures and recurrent status epilepticus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/86\">",
"     86",
"    </a>",
"    ]. Motor seizures may respond to intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , and pyridoxine. Noteworthy is the finding that during seizures, the electrocardiogram may remain normal despite elevated mexiletine concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16750559\">",
"    <span class=\"h2\">",
"     Inhibitor of CYP1A2",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"     Mexiletine",
"    </a>",
"    is a potent CYP1A2 inhibitor and co-administration of mexiletine increases plasma concentrations of substrates for cytochrome P450 (CYP) 1A2 such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/87\">",
"     87",
"    </a>",
"    ], caffeine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/87,88\">",
"     87,88",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    (a new antispastic agent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/89\">",
"     89",
"    </a>",
"    ]. Mexiletine, approved for managing pain, painful neuropathies, and headache when used in conjunction with tizanidine may cause unpredictable changes in plasma concentrations and pharmacodynamic effects and should be used with care as it is with other substrates for cytochrome P450 (CYP)1A2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747200\">",
"    <span class=\"h1\">",
"     FLECAINIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    is an effective agent against both ventricular and supraventricular arrhythmias. However, its use is limited by concern about toxicity, particularly its proarrhythmic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752027\">",
"    <span class=\"h2\">",
"     Cardiac toxicity",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752035\">",
"    <span class=\"h3\">",
"     Proarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    was one of two class IC antiarrhythmic medications included in the CAST trial, which evaluated patients with asymptomatic, non-life-threatening ventricular arrhythmias who were six days to two years after an acute myocardial infarction (MI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/91\">",
"     91",
"    </a>",
"    ]. CAST was initiated with the hypothesis that patients with ventricular premature beats (VPBs) or episodes of nonsustained ventricular tachycardia (NSVT) were at increased risk of an arrhythmic death and that suppression of these ventricular arrhythmias would improve survival. To the contrary, flecainide had an apparent proarrhythmic effect with a significantly",
"    <strong>",
"     increased",
"    </strong>",
"    incidence of mortality plus nonfatal cardiac arrest (6.1 percent versus 2.3 percent in the placebo group).",
"   </p>",
"   <p>",
"    The mechanism of the increase in mortality is not well understood. It has been proposed that the increase in malignant arrhythmias was due to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    in the setting of ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac structural abnormalities (eg scar from the prior infarction). This hypothesis is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients in the CAST trial had prior MI.",
"     </li>",
"     <li>",
"      A case series of three patients without CHD who developed ventricular arrhythmias after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      use for atrial fibrillation included one patient with a prosthetic mitral valve, one patient with hypertrophic cardiomyopathy, and one patient without known cardiac structural abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       Flecainide",
"      </a>",
"      did not increase mortality when used for the treatment of supraventricular arrhythmias in structurally normal hearts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752042\">",
"    <span class=\"h3\">",
"     Conduction abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to its significant effect on sodium channels,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    prolongs depolarization and can slow conduction in the AV node, the His-Purkinje system, and below. These changes can lead to prolongation of the PR interval, increased QRS duration, and first- and second-degree heart block. In addition, profound sinus bradycardia can be induced in patients with preexisting sinus node disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/94\">",
"     94",
"    </a>",
"    ]. In contrast, flecainide does not affect repolarization and therefore has little effect on the QT interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752049\">",
"    <span class=\"h3\">",
"     Hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    has a negative inotropic effect that can cause or worsen heart failure. The incidence of this complication varies from less than 1 to 6 percent. Patients at increased risk are those with preexisting New York Heart Association Class III or IV heart failure; the use of flecainide to treat sustained ventricular tachycardia in these settings can worsen the heart failure in up to 25 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752056\">",
"    <span class=\"h2\">",
"     Extracardiac effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    can induce a variety of generally mild and tolerable noncardiac side effects. These include dizziness, blurred vision or difficulty in focusing, headache, and nausea, each of which occurs in 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752063\">",
"    <span class=\"h2\">",
"     Overall safety profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac safety profile of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    was assessed in 227 outpatients with paroxysmal atrial fibrillation (PAF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/98\">",
"     98",
"    </a>",
"    ]. Patients were treated with 200 mg daily for 24 weeks. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean QRS duration increase was 11.4 percent, and 19 percent of patients had &ge;25 percent increase in QRS duration.",
"     </li>",
"     <li>",
"      Significant left ventricular ejection fraction reduction occurred in 1.4 percent of patients.",
"     </li>",
"     <li>",
"      Bradycardia (13.2 percent) and ventricular extrasystoles (10.6 percent) were the most frequently identified proarrhythmic effects.",
"     </li>",
"     <li>",
"      Other adverse cardiac events included atrioventricular block (4.0 percent), supraventricular tachycardia (2.2 percent), bundle branch block (1.8 percent) and atrial fibrillation (1.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752070\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high burden of comorbid disease and concomitant drug use in a large proportion of patients with AF limits the suitability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    for many patients. Cardiac conditions such as bradycardia, history of MI, and structural heart disease, and noncardiac conditions such as renal disease, pulmonary disease, liver disease, thyroid dysfunction and diabetes mellitus limit its use.",
"   </p>",
"   <p>",
"    In the Canadian Registry of Atrial Fibrillation (CARAF) cohort of 723 patients with new onset AF, 57 percent had contraindications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    warnings at baseline that might prevent the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752077\">",
"    <span class=\"h3\">",
"     Outpatient initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    is usually initiated in the hospital. However, in a selected risk-stratified population of patients with recurrent atrial fibrillation, outpatient initiation of flecainide appears to be safe. This is referred to as the \"pill-in-the-pocket\" strategy, and it is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H8701769#H8701769\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Flecainide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752084\">",
"    <span class=\"h2\">",
"     Long QT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies have shown that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    corrects the abnormality associated with long QT-3 (DeltaKPQ deletion). The safety and efficacy of flecainide was compared to placebo in a small group of LQT-3 male (n = 6) patients with the DeltaKPQ deletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/100\">",
"     100",
"    </a>",
"    ]. Minimal prolongation in QRS occurred (mean: +2.5 ms), and there were no major adverse cardiac effects, although the sample size is not large enough to evaluate the safety of flecainide therapy in patients with this mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752091\">",
"    <span class=\"h2\">",
"     Neurotoxicity associated with renal dysfunction and inhibition of CYP2D6",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752099\">",
"    <span class=\"h3\">",
"     Renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    accumulates in patients with renal failure; close monitoring of levels is needed. Although the absorption and volume of distribution of flecainide are unaffected by renal failure, the plasma elimination half-life is prolonged in mild to moderate renal impairment (10 to 30 h) compared to normal renal function (6 to 15 h). Moreover, the half-life increases further in patients with stage 5 chronic kidney disease (up to 40 h) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/101\">",
"     101",
"    </a>",
"    ]. Since flecainide is not removed efficiently by dialysis there is a potential for toxicity in patients undergoing dialysis.",
"   </p>",
"   <p>",
"    Renal failure may predispose to toxicity at lower serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    concentrations and cause severe neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. While dizziness and visual disturbances, including diplopia, are not unusual, severe neurologic complications are rare. However, they include paranoid psychosis, dysarthria, visual hallucinations, generalized seizures and cerebello-myoclonic syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752106\">",
"    <span class=\"h3\">",
"     CYP2D6 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    is a substrate of the hepatic enzyme system CYP2D6, which is inhibited by the selective serotonin-reuptake inhibitors (SSRIs),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    . Thus, these CYP2D6 inhibitors also have the potential to cause central nervous system toxicity with flecainide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752113\">",
"    <span class=\"h2\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazide diuretics, when used with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , may act to exacerbate electrolyte loss. In this setting hyponatremia-induced flecainide cardio-toxicity has been described. The cellular mechanism is thought to involve antagonism of the interaction of flecainide with the sodium channel via sodium ions. Flecainide has also been shown to reduce transepithelial sodium and water absorption in animal studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747208\">",
"    <span class=\"h1\">",
"     PROPAFENONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 20 percent of patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    will have side effects that require drug discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. The most common adverse reactions involve the gastrointestinal, central nervous, and cardiovascular systems. Most of these complications are dose-dependent, particularly central nervous system side effects such as dizziness, nausea, unusual taste, and blurred vision, which are often ameliorated if the propafenone dose is reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/108\">",
"     108",
"    </a>",
"    ]. Potential side effects involving the cardiovascular system are most concerning, as the cardiac side effects are the most life-threatening. The risk of cardiovascular toxicity is greater in patients with structural heart disease and in those treated for ventricular rather than supraventricular arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/108,109\">",
"     108,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relation between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    dosage, concentration, clinical response, and toxicity is complex. The main metabolic route of propafenone is via the cytochrome P450 2D6 isoenzyme. This metabolic pathway, known to have genetic polymorphisms, is functionally absent in about seven percent of whites and African Americans. In these \"slow metabolizers,\" the extent of first-pass hepatic metabolism is much less than in \"extensive metabolizers,\" and increased plasma concentration may be more likely to cause side effects. Moreover, because the oxidative elimination of propafenone is saturable, small dosage increases may cause a rapid and disproportionate increase in plasma concentrations, thus augmenting its potential for causing toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16751133\">",
"    <span class=\"h2\">",
"     Cardiovascular effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16751140\">",
"    <span class=\"h3\">",
"     Inotropic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    and its metabolites can have negative inotropic effects on the myocardium. In patients with a normal or minimally decreased left ventricular ejection fraction (&ge;40 percent), oral propafenone can decrease the ejection fraction without causing symptoms of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/111\">",
"     111",
"    </a>",
"    ]. However, overt heart failure may be induced in patients with preexisting ventricular systolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/112\">",
"     112",
"    </a>",
"    ]. The negative inotropic effect of propafenone is associated with significant increases in pulmonary capillary wedge pressure and in systemic and pulmonary vascular resistance and a decline in cardiac output. Propafenone should therefore be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with overt heart failure. However, propafenone can be administered cautiously to patients with mildly reduced left ventricular ejection fraction who have no clinical signs or symptoms of heart failure, with close monitoring over one to two weeks for the development of heart failure symptoms following the initiation of therapy. If heart failure symptoms develop after the initiation of propafenone, the drug should be discontinued.",
"   </p>",
"   <p>",
"    The role of beta-blockade in the decline in contractility induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    is unclear. Although the direct effect of blocking the beta-receptors is to impair contractility, the associated reduction in neurohumoral activation may lead to an improvement in cardiac function in patients with heart failure. Clinically significant beta-blocking activity is primarily seen at high doses in patients who are slow metabolizers of propafenone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16751147\">",
"    <span class=\"h3\">",
"     Chronotropic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     Propafenone",
"    </a>",
"    has a variety of effects that can lead to bradycardia including its Class IC activity and its beta-blocker and calcium channel blocker properties. As a result, patients with known sinus node dysfunction, including the sick sinus syndrome, should",
"    <strong>",
"     not",
"    </strong>",
"    receive propafenone in the absence of a permanent pacemaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/113\">",
"     113",
"    </a>",
"    ]. Alternatively, because potential variations in propafenone metabolism may exist and remain undetected in everyday practice, some authors have suggested a heart rate challenge, such as exercise testing, for patients using chronic propafenone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16751154\">",
"    <span class=\"h3\">",
"     Conduction disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     Propafenone",
"    </a>",
"    slows atrioventricular conduction and causes prolongation of the PR and QRS intervals. Prolongation of the PR interval ranges from 15 to 25 percent; it is a common finding and is not necessarily regarded as a sign of toxicity. However, on rare occasions propafenone has been associated with the development of atrioventricular block. Therefore, in the absence of a permanent pacemaker, patients on propafenone who develop second or third degree AV block should have their dose of propafenone reduced or discontinued.",
"   </p>",
"   <p>",
"    Sodium channel blockade is probably responsible for QRS prolongation during exercise in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    . Propafenone has been associated with QRS prolongation, new left bundle branch block, and new right bundle branch block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. These conduction disturbances usually occur in patients with underlying heart disease and appear to be dose-dependent. No specific dose adjustments are required in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16751161\">",
"    <span class=\"h3\">",
"     Proarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other antiarrhythmic agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    has a proarrhythmic effect that can trigger sustained ventricular tachycardia (VT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/15\">",
"     15",
"    </a>",
"    ]. The proarrhythmic effect of propafenone may be somewhat reduced by its beta-blocking activity.",
"   </p>",
"   <p>",
"    The potential for proarrhythmia is greater with the class IC agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , compared to the IA or IB drugs (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"mobipreview.htm?2/52/2892\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/117\">",
"     117",
"    </a>",
"    ]. The overall incidence of proarrhythmia with propafenone is approximately five percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. The risk of proarrhythmia appears greatest in those with underlying structural heart disease. The two most powerful predictors of proarrhythmia are previous VT and decreased left ventricular ejection fraction. Patients with known structural heart disease should",
"    <strong>",
"     not",
"    </strong>",
"    receive propafenone. Propafenone should be discontinued in patients who develop sustained VT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16751168\">",
"    <span class=\"h2\">",
"     CNS side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of adverse central nervous system (CNS) effects have been reported in association with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , with dizziness being the most common along with nausea, unusual taste, and blurred vision. Ataxia caused by propafenone has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the side effects of the drug are usually dose-related, the precise mechanism is not fully understood. Blockade of beta-adrenergic receptors may be partly responsible, because this action can in itself cause CNS symptoms including sleep disturbance, depression, drowsiness, fatigue, lethargy, hallucination, delirium, paranoia, and amnesia. The blockade of fast inward sodium channels by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    may also contribute to its CNS adverse effects.",
"   </p>",
"   <p>",
"    In patients who develop CNS effects from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , it is reasonable to consider lowering the dose in an effort to reduce side effects. If CNS side effects persist, propafenone should be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16751175\">",
"    <span class=\"h2\">",
"     Gastrointestinal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal side effects from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , usually mild in nature, are among the most commonly reported adverse effects. Up to 20 percent of patients receiving propafenone report an unusual taste sensation, and up to 10 percent of patients develop nausea. The frequency of these side effects may be reduced if patients take the medication with food. If the adverse effects continue and are intolerable to the patient, propafenone should be discontinued.",
"   </p>",
"   <p>",
"    Acute cholestatic hepatitis associated with use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/121\">",
"     121",
"    </a>",
"    ]. The relationship between the administration of propafenone, acute onset of liver damage, exclusion of hepatobiliary disease and rapid normalization of biochemical parameters following drug withdrawal suggests that propafenone is involved in the pathogenesis of liver failure in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16751182\">",
"    <span class=\"h2\">",
"     Pulmonary side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any drug that has beta-blocking activity,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    should be used cautiously in patients with reactive airway disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/122\">",
"     122",
"    </a>",
"    ]. The potential deleterious effects of beta blockers on airway function are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link&amp;anchor=H7#H7\">",
"     \"Major side effects of beta blockers\", section on 'Increased airways resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17898?source=see_link&amp;anchor=H81297784#H81297784\">",
"     \"Management of the patient with severe COPD and cardiovascular disease\", section on 'Treatment of CVD in patients with COPD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16751189\">",
"    <span class=\"h2\">",
"     Dermatologic side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    are rare. Among these complications, the most common is a lupus erythematosus-like syndrome, which presents with photosensitivity and pruriginous erythema (red, itchy, papules) on the face, forehead, and cheeks. Propafenone can also be associated with acute generalized exanthematous pustulosis, a cutaneous reaction accompanied by fever and neutrophilia, characterized by an acute eruption with numerous small nonfollicular sterile pustules overlying an erythematous and edematous background [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/123\">",
"     123",
"    </a>",
"    ]. Treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , 100 mg, four times per day has been associated with resolution, followed by postinflammatory desquamation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16751196\">",
"    <span class=\"h2\">",
"     Propafenone intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;While adverse reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    are relatively common, reports of death secondary to propafenone intoxication are comparatively rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/124\">",
"     124",
"    </a>",
"    ]. Heart failure, conduction disturbances, and seizures are major clinical signs of intoxication.",
"   </p>",
"   <p>",
"    In the setting of overdose and intoxication,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    may cause hemodynamically-unstable ventricular tachyarrhythmias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bradyarrhythmias. Overdoses may also induce congestive heart failure and hypotension due to excessive negative inotropic effects on the myocardium.",
"   </p>",
"   <p>",
"    Seizures are an important clinical sign of overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/124\">",
"     124",
"    </a>",
"    ]. While the exact etiology of the seizure activity remains unclear, direct neurotoxicity or cerebral hypoperfusion related to arrhythmias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    conduction disturbances are possible mechanisms.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     Propafenone",
"    </a>",
"    intoxication is associated with ingested doses from 1800 to 9000 mg and serum concentrations as high as 12,000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    have been reported (normal therapeutic and toxic ranges for propafenone are 400 to 1100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and 1100 to 2000",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/124,125\">",
"     124,125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    intoxication centers on hemodynamic support and includes intravenous glucagon (to reverse any toxicity due to the beta blocker effects), hypertonic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , hypertonic saline, and inotropic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/9/37018/abstract/125\">",
"     125",
"    </a>",
"    ]. A temporary pacemaker may be required for patients with high-degree AV block related to the overdose. Routine blood testing for propafenone levels should be performed in patients following resuscitation, particularly in patients undergoing treatment for arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link&amp;anchor=H12#H12\">",
"     \"General approach to drug poisoning in adults\", section on 'Poisoning management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16747216\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752439\">",
"    <span class=\"h2\">",
"     Class IA antiarrhythmics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      is associated with a number of anticholinergic symptoms, including dry mouth, urinary hesitancy, and constipation. In addition, disopyramide has several cardiac effects, including negative inotropic activity (potentially resulting in heart failure) and proarrhythmia with lengthening of the QT interval (potentially resulting in polymorphic ventricular tachycardia). (See",
"      <a class=\"local\" href=\"#H16747152\">",
"       'Disopyramide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of nonspecific systemic symptoms can be induced by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , including gastrointestinal disturbances, central nervous system dysfunction, fever, rash, and myalgias. Chronic administration of procainamide is associated with a positive antinuclear antibody titer in almost all patients, particularly slow acetylators, with symptoms similar to those seen in lupus (eg, arthritis, arthralgias, and pleuritis) in 15 to 20 percent of patients. Additionally, a variety of more serious and potentially lethal cardiac effects are more common at toxic plasma levels (above 30",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      for procainamide plus its major metabolite N-acetylprocainamide versus a therapeutic range of 4 to 12",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      for procainamide alone), including conduction delay (with PR prolongation or QRS widening), QT prolongation, ventricular tachyarrhythmias, increased AV nodal conduction, and depressed left ventricular function. (See",
"      <a class=\"local\" href=\"#H16747160\">",
"       'Procainamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequent adverse effects with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      are gastrointestinal, including nausea, diarrhea, and abdominal bloating and discomfort. Central nervous system toxicity is associated with high-dose therapy and subsequent high plasma quinidine levels. The constellation of symptoms that may be seen is called cinchonism and includes tinnitus, hearing loss, confusion, delirium, disturbances in vision, and psychosis. Additionally, a variety of potential cardiac toxicities may result from the administration of quinidine, including proarrhythmia with lengthening of the QT interval (potentially resulting in polymorphic ventricular tachycardia), slowed AV nodal conduction (potentially leading to heart block), and hypotension. (See",
"      <a class=\"local\" href=\"#H16747168\">",
"       'Quinidine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752447\">",
"    <span class=\"h2\">",
"     Class IB antiarrhythmics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      , administered intravenously in the treatment of ventricular arrhythmias, is generally well tolerated. The major side effects with intravenous lidocaine primarily involve the central nervous system (eg, tremor, insomnia or drowsiness, lightheadedness, ataxia, agitation), the gastrointestinal tract (nausea, vomiting, and anorexia), and the cardiovascular system (eg, sinus slowing, asystole, hypotension, and shock). (See",
"      <a class=\"local\" href=\"#H16747176\">",
"       'Lidocaine (intravenous)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The side effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/9/10389?source=see_link\">",
"       mexiletine",
"      </a>",
"      are generally dose- and concentration-dependent. The most common adverse effects are related to the gastrointestinal tract (eg, nausea, vomiting, or heartburn) and central nervous system (eg, dizziness, lightheadedness, tremor, nervousness, difficulty with coordination, change in sleep habits, paresthesias, and numbness). As with many other antiarrhythmic agents, mexiletine also has a proarrhythmic effect which can contribute to ventricular tachyarrhythmias. (See",
"      <a class=\"local\" href=\"#H16747192\">",
"       'Mexiletine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16752455\">",
"    <span class=\"h2\">",
"     Class IC antiarrhythmics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       Flecainide",
"      </a>",
"      is generally well tolerated, though it can induce a variety of generally mild and tolerable noncardiac side effects, including dizziness, blurred vision or difficulty in focusing, headache, and nausea, each of which occurs in 10 to 20 percent of patients. Flecainide is associated with proarrhythmia and the potential for fatal ventricular arrhythmias in persons with structural heart disease. Conversely, flecainide does not appear to increase mortality when used for the treatment of supraventricular arrhythmias in persons with structurally normal hearts. (See",
"      <a class=\"local\" href=\"#H16747200\">",
"       'Flecainide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 15 to 20 percent of patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      will have side effects that require drug discontinuation. Most commonly, adverse reactions involve the gastrointestinal (nausea and an unusual taste sensation), central nervous (most commonly dizziness), and cardiovascular systems. Propafenone has several cardiovascular effects that can lead to limitations in its use, including negative inotropic effects, bradycardia and AV block, and proarrhythmia. Propafenone intoxication, often due to overdose, is a life-threatening condition marked by heart failure, hemodynamically-unstable ventricular tachyarrhythmias",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bradyarrhythmias, and seizures. (See",
"      <a class=\"local\" href=\"#H16747208\">",
"       'Propafenone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/1\">",
"      Teichman SL, Ferrick A, Kim SG, et al. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. J Am Coll Cardiol 1987; 10:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/2\">",
"      Konishi T, Kadoya M, Ikeguchi S, et al. Combined effect of disopyramide and bethanechol: use of bethanechol to prevent anticholinergic side effects of disopyramide without reduction of antiarrhythmic efficacy. J Cardiovasc Pharmacol 1989; 14:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/3\">",
"      Tsuchishita Y, Fukumoto K, Kusumoto M, Ueno K. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide. Biol Pharm Bull 2008; 31:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/4\">",
"      Di Bianco R, Gottdiener JS, Singh SN, Fletcher RD. A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation. Angiology 1987; 38:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/5\">",
"      Walsh RA, Horwitz LD. Adverse hemodynamic effects of intravenous disopyramide compared with quinidine in conscious dogs. Circulation 1979; 60:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/6\">",
"      O'Keeffe B, Hayler AM, Holt DW, Medd RK. Cardiac consequences and treatment of disopyramide intoxication: experimental evaluation in dogs. Cardiovasc Res 1979; 13:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/7\">",
"      Jensen G, Sigurd B, Uhrenholt A. Haemodynamic effects of intravenous disopyramide in heart failure. Eur J Clin Pharmacol 1975; 8:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/8\">",
"      Story JR, Abdulla AM, Frank MJ. Cardiogenic shock and disopyramide phosphate. JAMA 1979; 242:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/9\">",
"      Casedevant B, Sabaut D, Clementy J, Dallocchio M. [Letter: Syncopes through the inversion of points in connection with the absorption of disopyramide]. Nouv Presse Med 1975; 4:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/10\">",
"      Choudhury L, Grais IM, Passman RS. Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis 1999; 1:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/11\">",
"      Hayashi Y, Ikeda U, Hashimoto T, et al. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 1999; 22:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/12\">",
"      Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/13\">",
"      Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001; 18 Suppl 1:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/14\">",
"      Granowitz EV, Tabor KJ, Kirchhoffer JB. Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol 2000; 23:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/15\">",
"      Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. Am J Cardiol 1987; 59:38E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/16\">",
"      Wald RW, Waxman MB, Colman JM. Torsade de pointes ventricular tachycardia. A complication of disopyramide shared with quinidine. J Electrocardiol 1981; 14:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/17\">",
"      Schweitzer P, Mark H. Torsade de pointes caused by disopyramide and hypokalemia. Mt Sinai J Med 1982; 49:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/18\">",
"      Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/19\">",
"      Tzivoni D, Keren A, Stern S, Gottlieb S. Disopyramide-induced Torsade de Pointes. Arch Intern Med 1981; 141:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/20\">",
"      Semel JD, Wortham E, Karl DM. Fasting hypoglycemia associated with disopyramide. Am Heart J 1983; 106:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/21\">",
"      Croxson MS, Shaw DW, Henley PG, Gabriel HD. Disopyramide-induced hypoglycaemia and increased serum insulin. N Z Med J 1987; 100:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/22\">",
"      Negishi M, Shimomura K, Proks P, et al. Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med 2009; 26:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/23\">",
"      Iida H, Morita T, Suzuki E, et al. Hypoglycemia induced by interaction between clarithromycin and disopyramide. Jpn Heart J 1999; 40:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/24\">",
"      Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/25\">",
"      Stec GP, Lertora JJ, Atkinson AJ Jr, et al. Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy. Ann Intern Med 1979; 90:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/26\">",
"      Reidenberg MM, Drayer DE. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus. Angiology 1986; 37:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/27\">",
"      Danielly J, DeJong R, Radke-Mitchell LC, Uprichard AC. Procainamide-associated blood dyscrasias. Am J Cardiol 1994; 74:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/28\">",
"      Ellrodt AG, Murata GH, Riedinger MS, et al. Severe neutropenia associated with sustained-release procainamide. Ann Intern Med 1984; 100:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/29\">",
"      Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/30\">",
"      Reiter MJ, Higgins SL, Payne AG, Mann DE. Effects of quinidine versus procainamide on the QT interval. Am J Cardiol 1986; 58:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/31\">",
"      Perkins A, Marill K. Accelerated AV nodal conduction with use of procainamide in atrial fibrillation. J Emerg Med 2012; 42:e47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/32\">",
"      Wisenberg G, Zawadowski AG, Gebhardt VA, et al. Effects on ventricular function of disopyramide, procainamide and quinidine as determined by radionuclide angiography. Am J Cardiol 1984; 53:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/33\">",
"      Austen WG, Moran JM. Cardiac and peripheral vascular effects of lidocaine and procainamide. Am J Cardiol 1965; 16:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/34\">",
"      Folle LE, Aviado DM. The cardiopulmonary effects of quinidine and procainamide. J Pharmacol Exp Ther 1966; 154:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/35\">",
"      Jaillon P, Winkle RA. Electrophysiologic comparative study of procainamide and N-acetylprocainamide in anesthetized dogs: concentration-response relationships. Circulation 1979; 60:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/36\">",
"      Mandel WJ, Laks MM, Arieff AI, et al. Cardiorenal effects of lidocaine and procaine amide in the conscious dog. Am J Physiol 1975; 228:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/37\">",
"      Marill KA, deSouza IS, Nishijima DK, et al. Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: an historical multicenter comparison. Acad Emerg Med 2010; 17:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/38\">",
"      Murray KD, Vlasnik JJ. Procainamide-induced postoperative pyrexia. Ann Thorac Surg 1999; 68:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/39\">",
"      Bizjak ED, Nolan PE Jr, Brody EA, Galloway JM. Procainamide-induced psychosis: a case report and review of the literature. Ann Pharmacother 1999; 33:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/40\">",
"      Cohen IS, Jick H, Cohen SI. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 1977; 20:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/41\">",
"      Morganroth J, Horowitz LN. Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias. Am J Cardiol 1985; 56:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/42\">",
"      Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986; 111:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/43\">",
"      SELZER A, WRAY HW. QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS. Circulation 1964; 30:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/44\">",
"      Koster RW, Wellens HJ. Quinidine-induced ventricular flutter and fibrillation without digitalis therapy. Am J Cardiol 1976; 38:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/45\">",
"      Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol 1987; 59:32E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/46\">",
"      Minardo JD, Heger JJ, Miles WM, et al. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med 1988; 319:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/47\">",
"      Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res 1985; 56:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/48\">",
"      Levine JH, Spear JF, Guarnieri T, et al. Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo. Circulation 1985; 72:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/49\">",
"      Smith WM, Gallagher JJ. \"Les torsades de pointes\": an unusual ventricular arrhythmia. Ann Intern Med 1980; 93:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/50\">",
"      Keren A, Tzivoni D, Gavish D, et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation 1981; 64:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/51\">",
"      WASSERMAN F, BRODSKY L, KATHE JH, et al. The effect of molar sodium lactate in quinidine intoxication. Am J Cardiol 1959; 3:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/52\">",
"      Mason JW, Hondeghem LM. Quinidine. Ann N Y Acad Sci 1984; 432:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/53\">",
"      Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997; 96:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/54\">",
"      El-Eraky H, Thomas SH. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. Br J Clin Pharmacol 2003; 56:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/55\">",
"      Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/56\">",
"      SHORT DS. The syndrome of alternating bradycardia and tachycardia. Br Heart J 1954; 16:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/57\">",
"      Grayzel J, Angeles J. Sino-atrial block in man provoked by quinidine. J Electrocardiol 1972; 5:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/58\">",
"      Motulsky HJ, Maisel AS, Snavely MD, Insel PA. Quinidine is a competitive antagonist at alpha 1- and alpha 2-adrenergic receptors. Circ Res 1984; 55:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/59\">",
"      Mason JW, Winkle RA, Ingels NB, et al. Hemodynamic effects of intravenously administered quinidine on the transplanted human heart. Am J Cardiol 1977; 40:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/60\">",
"      Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed) 1986; 292:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/61\">",
"      Trampuz A, Jereb M, Muzlovic I, Prabhu RM. Clinical review: Severe malaria. Crit Care 2003; 7:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/62\">",
"      SHULMAN NR. Immunoreactions involving platelets. I. A steric and kinetic model for formation of a complex from a human antibody, quinidine as a haptene, and platelets; and for fixation of complement by the complex. J Exp Med 1958; 107:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/63\">",
"      Cohen MG, Kevat S, Prowse MV, Ahern MJ. Two distinct quinidine-induced rheumatic syndromes. Ann Intern Med 1988; 108:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/64\">",
"      Min DI, Ku YM, Geraets DR, Lee H. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol 1996; 36:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/65\">",
"      Lafuente-Lafuente C, Mouly S, Long&aacute;s-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006; 166:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/66\">",
"      Rademaker AW, Kellen J, Tam YK, Wyse DG. Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clin Pharmacol Ther 1986; 40:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/67\">",
"      Chopra MP, Thadani U, Portal RW, Aber CP. Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double-blind trial. Br Med J 1971; 3:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/68\">",
"      Gianelly R, von der Groeben JO, Spivack AP, Harrison DC. Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. N Engl J Med 1967; 277:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/69\">",
"      Lown B, Vassaux C. Lidocaine in acute myocardial infarction. Am Heart J 1968; 76:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/70\">",
"      DeToledo JC. Lidocaine and seizures. Ther Drug Monit 2000; 22:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/71\">",
"      Pfeifer HJ, Greenblatt DJ, Koch-Weser J. Clinical use and toxicity of intravenous lidocaine. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J 1976; 92:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/72\">",
"      Schumacher RR, Lieberson AD, Childress RH, Williams JF Jr. Hemodynamic effects of lidocaine in patients with heart disease. Circulation 1968; 37:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/73\">",
"      Dorian P, Fain ES, Davy JM, Winkle RA. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements. J Am Coll Cardiol 1986; 8:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/74\">",
"      Johansson BW, Stavenow L, Hanson A. Long-term clinical experience with mexiletine. Am Heart J 1984; 107:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/75\">",
"      Talbot RG, Julian DG, Prescott LF. Long-term treatment of ventricular arrhythmias with oral mexiletine. Am Heart J 1976; 91:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/76\">",
"      Fasola GP, D'Osualdo F, de Pangher V, Barducci E. Thrombocytopenia and mexiletine. Ann Intern Med 1984; 100:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/77\">",
"      Velebit V, Podrid P, Lown B, et al. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982; 65:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/78\">",
"      Campbell RW. Arrhythmogenesis--a European perspective. Am J Cardiol 1987; 59:49E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/79\">",
"      Sami M, Lisbona R. Mexiletine: long-term efficacy and hemodynamic actions in patients with ventricular arrhythmia. Can J Cardiol 1985; 1:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/80\">",
"      Shanks RG. Hemodynamic effects of mexiletine. Am Heart J 1984; 107:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/81\">",
"      Stein J, Podrid P, Lown B. Effects of oral mexiletine on left and right ventricular function. Am J Cardiol 1984; 54:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/82\">",
"      Gottlieb SS, Weinberg M. Cardiodepressant effects of mexiletine in patients with severe left ventricular dysfunction. Eur Heart J 1992; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/83\">",
"      Sasaki K, Yamamoto T, Kishi M, et al. Acute exanthematous pustular drug eruption induced by mexiletine. Eur J Dermatol 2001; 11:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/84\">",
"      Lee SP, Kim SH, Kim TH, et al. A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia. J Korean Med Sci 2010; 25:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/85\">",
"      Sekiguchi A, Kashiwagi T, Ishida-Yamamoto A, et al. Drug-induced hypersensitivity syndrome due to mexiletine associated with human herpes virus 6 and cytomegalovirus reactivation. J Dermatol 2005; 32:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/86\">",
"      Nelson LS, Hoffman RS. Mexiletine overdose producing status epilepticus without cardiovascular abnormalities. J Toxicol Clin Toxicol 1994; 32:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/87\">",
"      Kendall JD, Chrymko MM, Cooper BE. Theophylline-mexiletine interaction: a case report. Pharmacotherapy 1992; 12:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/88\">",
"      Hurwitz A, Vacek JL, Botteron GW, et al. Mexiletine effects on theophylline disposition. Clin Pharmacol Ther 1991; 50:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/89\">",
"      Momo K, Homma M, Osaka Y, et al. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 2010; 50:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/90\">",
"      Marmura MJ, Passero FC Jr, Young WB. Mexiletine for refractory chronic daily headache: a report of nine cases. Headache 2008; 48:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/91\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/92\">",
"      Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/93\">",
"      Pritchett EL, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991; 67:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/94\">",
"      Vik-Mo H, Ohm OJ, Lund-Johansen P. Electrophysiologic effects of flecainide acetate in patients with sinus nodal dysfunction. Am J Cardiol 1982; 50:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/95\">",
"      Hellestrand KJ, Bexton RS, Nathan AW, et al. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J 1982; 48:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/96\">",
"      Kjekshus J, Bathen J, Orning OM, Storstein L. A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. Am J Cardiol 1984; 53:72B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/97\">",
"      Gentzkow GD, Sullivan JY. Extracardiac adverse effects of flecainide. Am J Cardiol 1984; 53:101B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/98\">",
"      Aliot E, De Roy L, Capucci A, et al. Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. Ann Cardiol Angeiol (Paris) 2003; 52:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/99\">",
"      Humphries KH, Kerr CR, Steinbuch M, et al. Limitations to antiarrhythmic drug use in patients with atrial fibrillation. CMAJ 2004; 171:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/100\">",
"      Moss AJ, Windle JR, Hall WJ, et al. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 2005; 10:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/101\">",
"      Williams AJ, McQuinn RL, Walls J. Pharmacokinetics of flecainide acetate in patients with severe renal impairment. Clin Pharmacol Ther 1988; 43:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/102\">",
"      Ting SM, Lee D, Maclean D, Sheerin NS. Paranoid psychosis and myoclonus: flecainide toxicity in renal failure. Cardiology 2008; 111:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/103\">",
"      Ghika J, Goy JJ, Naegeli C, Regli F. Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy. Schweiz Arch Neurol Psychiatr 1994; 145:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/104\">",
"      Bennett MI. Paranoid psychosis due to flecainide toxicity in malignant neuropathic pain. Pain 1997; 70:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/105\">",
"      Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/106\">",
"      Lim KS, Cho JY, Jang IJ, et al. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol 2008; 66:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/107\">",
"      Khavandi A, Walker PR. Flecainide cardiotoxicity precipitated by electrolyte imbalance. Caution with thiazide diuretics. Emerg Med J 2007; 24:e26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/108\">",
"      Ravid S, Podrid PJ, Novrit B. Safety of long term propafenone therapy for cardiac arrhythmia: Experience with 774 patients. J Electrophysiol 1987; 1:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/109\">",
"      Podrid PJ, Anderson JL. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Am J Cardiol 1996; 78:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/110\">",
"      Schlepper M. Propafenone, a review of its profile. Eur Heart J 1987; 8 Suppl A:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/111\">",
"      Baker BJ, Dinh H, Kroskey D, et al. Effect of propafenone on left ventricular ejection fraction. Am J Cardiol 1984; 54:20D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/112\">",
"      Brodsky MA, Allen BJ, Abate D, Henry WL. Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. Am Heart J 1985; 110:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/113\">",
"      Stohler JL, Kowey PR, Marinchak RA, Friehling TD. Drug interactions with propafenone. J Electrophysiol 1987; 1:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/114\">",
"      Dilaveris P, Synetos A, Giannopoulos G, et al. Exercise-induced left bundle branch block and propafenone administration. Int J Cardiology 2006; 106: 279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/115\">",
"      de Soyza N, Terry L, Murphy ML, et al. Effect of propafenone in patients with stable ventricular arrhythmias. Am Heart J 1984; 108:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/116\">",
"      Podrid PJ, Lown B. Propafenone: a new agent for ventricular arrhythmia. J Am Coll Cardiol 1984; 4:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/117\">",
"      Dhein S, M&uuml;ller A, Gerwin R, Klaus W. Comparative study on the proarrhythmic effects of some antiarrhythmic agents. Circulation 1993; 87:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/118\">",
"      Buss J, Neuss H, Bilgin Y, Schlepper M. Malignant ventricular tachyarrhythmias in association with propafenone treatment. Eur Heart J 1985; 6:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/119\">",
"      Stavens CS, McGovern B, Garan H, Ruskin JN. Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone. Am Heart J 1985; 110:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/120\">",
"      Odeh M, Seligmann H, Oliven A. Propafenone-induced ataxia: report of three cases. Am J Med Sci 2000; 320:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/121\">",
"      Gandolfi A, Rota E, Zanghieri G, et al. [Acute cholestatic hepatitis caused by propafenone. Report of a case and review of the literature]. Recenti Prog Med 2001; 92:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/122\">",
"      Hill MR, Gotz VP, Harman E, et al. Evaluation of the asthmogenicity of propafenone, a new antiarrhythmic drug. Comparison of spirometry with methacholine challenge. Chest 1986; 90:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/123\">",
"      Huang YM, Lee WR, Hu CH, Cheng KL. Propafenone-induced acute generalized exanthematous pustulosis. Int J Dermatol 2005; 44:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/124\">",
"      Clarot F, Goull&eacute; JP, Horst M, et al. Fatal propafenone overdoses: case reports and a review of the literature. J Anal Toxicol 2003; 27:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/9/37018/abstract/125\">",
"      Ovaska H, Ludman A, Spencer EP, et al. Propafenone poisoning--a case report with plasma propafenone concentrations. J Med Toxicol 2010; 6:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86747 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37018=[""].join("\n");
var outline_f36_9_37018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16747216\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16747152\">",
"      DISOPYRAMIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16747481\">",
"      Anticholinergic side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16747488\">",
"      Cardiac toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16747495\">",
"      - Electrocardiographic and proarrhythmic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16747502\">",
"      - Increased ventricular response during atrial fibrillation or flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16747509\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16747524\">",
"      Safety of disopyramide in obstructive hypertrophic cardiomyopathy (HCM)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16747160\">",
"      PROCAINAMIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16748111\">",
"      Systemic signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16748118\">",
"      Lupus-like syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16748125\">",
"      Blood dyscrasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16748132\">",
"      Cardiac toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16748139\">",
"      - Effects on ECG intervals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16748146\">",
"      Sinus rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16748153\">",
"      PR interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16748160\">",
"      QRS duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16748167\">",
"      QT interval",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16748174\">",
"      - Proarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16748181\">",
"      - Increased ventricular response during atrial fibrillation or flutter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16748188\">",
"      - Left ventricular dysfunction and vascular resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16748195\">",
"      Pyrexia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16748202\">",
"      Psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16747168\">",
"      QUINIDINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16749142\">",
"      Cardiovascular toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16749149\">",
"      - Proarrhythmia and ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16749156\">",
"      Treatment of torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16749163\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16749170\">",
"      Gender differences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16749177\">",
"      - Conduction disturbances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16749184\">",
"      - Hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16749191\">",
"      - Increased ventricular response during atrial fibrillation or flutter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16749198\">",
"      - Myocardial toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16749205\">",
"      Gastrointestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16749212\">",
"      Central nervous system toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16749219\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16749226\">",
"      Immune-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16749233\">",
"      Interaction with grapefruit juice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16749240\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16747176\">",
"      LIDOCAINE (INTRAVENOUS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16750194\">",
"      Neurologic toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16750201\">",
"      Cardiovascular toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16750208\">",
"      Gastrointestinal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16747192\">",
"      MEXILETINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16750517\">",
"      Cardiac complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16750524\">",
"      - Proarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16750531\">",
"      - Hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16750538\">",
"      Dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16750545\">",
"      Mexiletine-induced hypersensitivity syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16750552\">",
"      Overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16750559\">",
"      Inhibitor of CYP1A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16747200\">",
"      FLECAINIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16752027\">",
"      Cardiac toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16752035\">",
"      - Proarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16752042\">",
"      - Conduction abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16752049\">",
"      - Hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16752056\">",
"      Extracardiac effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16752063\">",
"      Overall safety profile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16752070\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16752077\">",
"      - Outpatient initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16752084\">",
"      Long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16752091\">",
"      Neurotoxicity associated with renal dysfunction and inhibition of CYP2D6",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16752099\">",
"      - Renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16752106\">",
"      - CYP2D6 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16752113\">",
"      Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16747208\">",
"      PROPAFENONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16751133\">",
"      Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16751140\">",
"      - Inotropic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16751147\">",
"      - Chronotropic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16751154\">",
"      - Conduction disturbances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16751161\">",
"      - Proarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16751168\">",
"      CNS side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16751175\">",
"      Gastrointestinal side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16751182\">",
"      Pulmonary side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16751189\">",
"      Dermatologic side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16751196\">",
"      Propafenone intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16747216\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16752439\">",
"      Class IA antiarrhythmics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16752447\">",
"      Class IB antiarrhythmics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16752455\">",
"      Class IC antiarrhythmics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/86747\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/86747|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/45/9950\" title=\"table 1\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/48/2830\" title=\"table 2\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/52/2892\" title=\"table 3\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/56/33676\" title=\"table 4\">",
"      Side effects of quinidine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17898?source=related_link\">",
"      Management of the patient with severe COPD and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13338?source=related_link\">",
"      Treatment of severe falciparum malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_9_37019="Mode of transmission of HIV in adolescents";
var content_f36_9_37019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modes of transmission of HIV in 13- to 19-year-olds, United States, 2010",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mode of transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Females",
"       </td>",
"       <td class=\"subtitle1\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heterosexual contact*",
"       </td>",
"       <td>",
"        92 percent",
"       </td>",
"       <td>",
"        4.7 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male-to-male sexual contact (MSM)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        91.2 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Injection drug use (IDU)",
"       </td>",
"       <td>",
"        8 percent",
"       </td>",
"       <td>",
"        1.3 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MSM + IDU",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        2.9 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus; NA: not applicable.",
"     <br>",
"      * Heterosexual contact with a person known to have or to be at high risk for HIV infection.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Centers for Disease Control and Prevention. HIV surveillance in adolescents and young adults. Available at:",
"     <a href=\"file://www.cdc.gov/hiv/topics/surveillance/resources/slides/adolescents/index.htm\" target=\"_blank\">",
"      file://www.cdc.gov/hiv/topics/surveillance/resources/slides/adolescents/index.htm",
"     </a>",
"     . Accessed on August 20, 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37019=[""].join("\n");
var outline_f36_9_37019=null;
var title_f36_9_37020="Medicolegal considerations CAM";
var content_f36_9_37020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medicolegal considerations in the use of complementary therapies in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Do parents elect to abandon effective care when the child's condition is serious or life-threatening?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Courts are likely to respect parental choices that are supported by some medical authority and that present reasonable alternatives as long as the child's life is not in danger and conventional care is not imminently necessary. The child's condition should be monitored conventionally so that conventional interventions can be used if necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Will the use of complementary and alternative medicine (CAM) therapy otherwise divert the child from imminently necessary conventional treatment?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If not, a \"time-limited\" trial of the proposed approach may be appropriate",
"        <sup>",
"         [1,2]",
"        </sup>",
"        , provided that the child can be monitored conventionally and conventional therapy can be continued as appropriate",
"        <sup>",
"         [3,4]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Are the CAM therapies that have been selected known to be unsafe or ineffective?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The medical evidence can be categorized as follows, with increasing risk of liability",
"        <sup>",
"         [3]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1) Medical evidence supports efficacy and safety.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2) Medical evidence supports safety, but evidence regarding efficacy is inconclusive.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3) Medical evidence supports efficacy, but evidence regarding safety is inconclusive.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4) Medical evidence indicates serious risk and inefficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The clinician caring for the patient should continue to monitor the patient and the literature for new information that would change the category.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Have the proper parties consented to the use of the CAM therapy?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Informed consent is particularly important when informing the patient about CAM therapies may affect the patient's choice of treatment",
"        <sup>",
"         [5]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Is the risk-benefit ratio of the proposed CAM therapy acceptable to a reasonable, similarly situated clinician, and does the therapy have at least minority acceptance or support in the medical literature?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        American Academy of Pediatrics. Pediatrics 2001; 107:598.",
"       </li>",
"       <li>",
"        Adams KE, Cohen MH, Eisenberg D, Jonsen AR. Ann Intern Med 2002; 137:660.",
"       </li>",
"       <li>",
"        Cohen MH, Eisenberg DM. Ann Intern Med 2002; 136:596.",
"       </li>",
"       <li>",
"        Eisenberg DM. Ann Intern Med 1997; 127:61.",
"       </li>",
"       <li>",
"        Ernst E, Cohen MH. Arch Intern Med 2001; 161:2288.",
"       </li>",
"      </ol>",
"      <br>",
"       Adapted from: Cohen MH, Kemper KJ. Complementary therapies in pediatrics: a legal perspective. Pediatrics 2005; 115:774.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37020=[""].join("\n");
var outline_f36_9_37020=null;
var title_f36_9_37021="Contents: Hair and scalp disease";
var content_f36_9_37021=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hair and scalp disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hair and scalp disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/38/10856\">",
"           Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/46/1768\">",
"           Clinical manifestations and diagnosis of alopecia areata",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/29/9690\">",
"           Evaluation and diagnosis of hair loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/0/31752\">",
"           Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/0/14344\">",
"           Female pattern hair loss (androgenetic alopecia in women): Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/14/4330\">",
"           Management of alopecia areata",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/33/13846\">",
"           Nonscarring hair loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/31/36343\">",
"           Pseudofolliculitis barbae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/50/23336\">",
"           Treatment of androgenetic alopecia in men",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-289200B00A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_9_37021=[""].join("\n");
var outline_f36_9_37021=null;
var title_f36_9_37022="US preterm birth rates";
var content_f36_9_37022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Preterm birth rates for all births and for singletons only: United States, 1990, 2000, and 2005",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 374px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Martin, JA, Hamilton, BE, Sutton, PD, et al. Births: Final Data for 2005. Natl Vital Stat Rep 2007; 56:1. Available at: file://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_06.pdf (Accessed March 13, 2009).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37022=[""].join("\n");
var outline_f36_9_37022=null;
var title_f36_9_37023="Esophagitis stricture";
var content_f36_9_37023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophagitis post esophageal stricture due to lye ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 9-year-old with hematemsis and a history of esophageal stricture secondary to lye ingestion. Endoscopy demonstrates patulous gastroesophageal junction with distal esophagus friability.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Murray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_9_37023=[""].join("\n");
var outline_f36_9_37023=null;
